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Abstract 
Nearly half of all youths experience a mental health disorder at some point during 
childhood (Merikangas et al., 2010). Pediatric psychopathology is associated with a substantial 
amount of impairment in the school, social, and home domains, and such symptoms can have 
adverse impacts on subsequent development (Beauchaine & Hinshaw, 2013; Patel, Flisher, 
Hetrick, & McGorry, 2007). Fortunately, a number of medications have demonstrated efficacy in 
treating a number of mental health conditions (Martin, Scahill, & Kratochvil, 2010). Despite 
these demonstrated effects, treatment response is often incomplete, and the mechanisms by 
which pharmacotherapy lead to behavior change are not well understood. However, research in 
pediatric psychopharmacology has often not considered the role of psychosocial variables, 
despite their promise to explain much variance in psychiatric outcomes and the robust influence 
they have demonstrated in psychotherapy-based behavior change (e.g., Shirk & Karver, 2011). 
This study investigated the role of four psychosocial variables in treatment outcome in pediatric 
psychiatric practice: medication adherence, therapeutic alliance, motivation for behavior change, 
and expectancies for positive treatment outcome. Surprising patterns of effects were found, with 
psychosocial variables being associated with both decreases and increases in symptomology 
depending on the circumstance (e.g., externalizing behavior), and many inconsistencies were 
observed among these patterns. While psychosocial variables are often portrayed as having 
uniformly positive impacts on treatment, their role in pediatric psychiatry may not be as 
straightforward as is commonly depicted in other diseases and therapeutic approaches. In 
 vi 
 
particular, the nature of their effects on outcome may vary across symptom presentations and 
intervention approaches. Based on these findings, recommendations for clinical practice and 
future research are discussed which affect all patients, researchers, and medical providers who 
participate in pediatric psychiatric treatment. 
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Introduction 
Psychiatric disorders in children are associated with devastating individual consequences 
and present an enormous public health burden. During childhood, 49.5% of youth experience a 
mental disorder at some point, and 22.2% of children experience symptoms that are 
characterized by severe impairment and/or distress (Merikangas et al., 2010). By adolescence, 
nearly two million American children perceive more than half of their days as “mentally 
unhealthy” (Perou et al., 2013). Pediatric psychopathology is also associated with impaired 
performance in the school, social, and home environments, and can lead to family disruption and 
even suicide (Beauchaine & Hinshaw, 2013). Such impairment is compounded longitudinally, as 
a majority of adults with mental disorders experience onset of symptoms during youth that 
continue to persist into adulthood (Kessler et al., 2005). This adversely affects the achievement 
of developmental milestones, including academic, vocational, and social goals (Patel, Flisher, 
Hetrick, & McGorry, 2007). These behavioral difficulties can also affect other health 
functioning; for instance, youth with mental disorders are at a higher risk of contracting HIV 
relative to peers without any mental disorders (Donenberg, 2005; Donenberg, Emerson, Bryant, 
Wilson, & Weber-Shifrin, 2001). On a broader level, the associated costs of mental illness in 
young people are staggering, as annual costs associated with pediatric mental illness are 
estimated at $247 billion dollars (Perou et al., 2013), and mental disorders are the costliest health 
condition to treat in children (Soni, 2009). As a whole, mental health problems in children are 
widespread, debilitating, and have detrimental effects on families, communities, and society. 
 2 
 
To address pediatric mental illness, two major approaches have been psychotherapy and 
medication treatment (Olfson, He, & Merikangas, 2013; Olfson & Marcus, 2010). While both 
modalities have displayed efficacy for a number of conditions (Kendall, 2011; Martin, Scahill, & 
Kratochvil, 2010), psychopharmacological interventions are used over five times more 
frequently than psychotherapy for youths (Olfson, Blanco, Wang, Laje, & Correll, 2014), and an 
estimated 14.2% of adolescents report taking a psychotropic medication in the preceding 12 
months (Merikangas, He, Rapoport, Vitiello, & Olfson, 2013). Medication use is also expanding 
over time, as the number of physician visits resulting in psychotropic medication prescriptions 
has more than doubled during the 15 year period prior to 2010 (Olfson, et al., 2014). However, 
the potential of side effects and adverse developmental impacts of medication use has led to 
some concern, especially given the extensive usage of pharmacotherapy in children. Also, while 
pharmacotherapy is frequently efficacious, real world treatment response is often incomplete 
(e.g., Franklin et al., 2011; The TADS Team, 2007; Walkup et al., 2008). Given that the 
development of new psychotropic agents has slowed greatly relative to the rest of medicine 
(Cowen, 2011), new “miracle drugs” to improve psychiatric outcomes are not on the 
developmental horizon. 
Given this context, what can be done to improve the real world effectiveness and safety 
of contemporary pharmacotherapy? Many efforts to address these concerns have manifested 
through the development of new pharmacological agents, which rely on an assumption that the 
mechanism of change in pharmacotherapy is largely biological. Unfortunately, this approach to 
pediatric psychopharmacology has led to limited improvements in patient outcomes in the past 
several decades. While some progress has been made in reducing side effects, newer 
pharmacological agents have not produced drastic improvements in patient outcomes (e.g., 
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Lieberman et al., 2005). As it currently stands, purely biological approaches to psychiatry have 
not produced fully optimal outcomes, and millions of children are not obtaining optimal 
symptom relief as a result. In addition, these suboptimal individual-level outcomes can aggregate 
into a large scale attenuation of therapeutic effects, leading to additional burden on the overall 
healthcare system when patients remain in active treatment for excessively long periods.  
However, a different approach is to directly incorporate psychosocial variables in 
pharmacotherapy approaches, which have demonstrated substantial impact on outcomes in 
psychotherapy and conventional medicine (e.g., Hall, Ferreira, Maher, Latimer, & Ferreira, 
2010; Osborn & Egede; Shirk, Karver, & Brown, 2011). These variables are known as “common 
factors” in the psychotherapy literature, as they have been highlighted for their importance across 
all methods of psychotherapy for over 70 years (Rosenzweig, 1936), but in the context of 
pharmacological interventions they have been characterized more frequently in terms of nuisance 
confounds  and “placebo effects” (Miller, Colloca, & Kaptchuk, 2009).  However, while 
psychosocial variables have often been considered to be research confounds, perhaps instead 
they can be construed as novel mechanisms to capitalize upon in order to provide new avenues 
for outcome improvement. At present, quantitative data to justify the roles of such variables are 
limited in pediatric psychiatry, but common factors are active in some capacity during all mental 
health treatment, including psychiatry (Patterson, 1985; Verhulst, Kramer, Swann, Hale-Richlen, 
& Beahrs, 2013). These psychosocial variables are also likely to work in tandem with biological 
treatments, as placebo effects have a variety of neuroendocrine consequences (e.g., modulation 
of neurotransmitter and hormonal functioning, changes in brain-based metabolism; Finniss, 
Kaptchuk, Miller, & Benedetti, 2010). To artificially dichotomize such effects as separate from 
biology results in imprecision in modeling the effects of pharmacotherapy for youth.  
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Among psychosocial variables, one factor that has received relatively little attention in 
pediatric psychiatry has been medication adherence, despite adherence rates being remarkably 
poor for a number of widely used medications (Brown & Bussell, 2011; Fischer et al., 2010). 
Another series of variables that have received limited empirical examination in pediatric 
psychiatry include the therapeutic alliance, motivation for behavior change, and expectancies for 
positive treatment outcome. These variables are readily available for modification and do not 
depend on hypothetical scientific developments in order to bring about improved patient 
outcomes. At present, patient adherence, therapeutic alliance, and patient expectancies and 
motivation remain understudied as active ingredients in pediatric psychiatry, as biological 
interventions are often construed as the integral active components. However, increasing the 
understanding of psychosocial variables in pediatric psychiatry could provide a foundation for 
innovative approaches that aim to improve care for a large number of patients. A review of 
relevant psychosocial variables follows. 
Considering the Role of Adherence in Pediatric Psychiatry 
Adherence refers to the extent that patients follow a prescribed medication regimen, and 
is critical to ensure the effectiveness of interventions (Osterberg & Blaschke, 2005). Indeed, 
billions of dollars in drug development are rendered ineffectual if patients do not take their 
medications as prescribed. In child psychiatry, adherence has often been observed to be poor, 
and adherence rates have been reported to be under 50% for commonly used medications such as 
serotonin reuptake inhibitors (frequently used for depression and anxiety) and stimulants 
(frequently used for attention-deficit/hyperactivity disorder, i.e., ADHD; Gau et al., 2006; 
Murray, de Vries, & Wong, 2004; Richardson, DiGiuseppe, Christakis, McCauley, & Katon, 
2004). While data on the adherence-outcome relationship are limited in pediatric 
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psychopharmacology, nonadherence to sertraline has been associated with a nearly 30% 
reduction in response rates in adult depression (von Knorring, Åkerblad, Bengtsson, Carlsson, & 
Ekselius, 2006). Psychiatric medication nonadherence is also a major contributor to drug-related 
emergency hospital admissions (Procyshyn, Barr, Brickell, & Honer, 2010), and poor medication 
adherence has been associated with increased rates of relapse and hospital readmission in 
patients with schizophrenia and bipolar disorder (Velligan et al., 2009). Conversely, 
improvements in adherence predict improved outcomes in treatment for pediatric ADHD and 
depression (Pappadopulos et al., 2009; Woldu et al., 2011). These adherence-outcome 
relationships are also seen in other fields of medicine, as meta-analytic estimates indicate that the 
difference between low and high adherence makes for a 26% difference in desired medical 
outcomes, and variability in adherence can compromise medical outcomes as much as 71% 
(DiMatteo, Giordani, Lepper, & Croghan, 2002). Poor adherence is not restricted to psychiatry 
and remains a common problem in a variety of chronic health conditions in youth, including 
diabetes, renal disease, and AIDS (DiMatteo, 2004). Inadequate adherence is also costly in terms 
of financial expenditures. Increases in costs ranging from $750 to $2,000 have been observed for 
each nonadhering patient in adult antidepressant treatment (Revicki, Simon, Chan, Katon, & 
Heiligenstein, 1998; Thompson, Peveler, Stephenson, & McKendrick, 2000), and costs 
associated with vocational absenteeism due to antidepressant noncompliance are over $1,000 
annually per nonadherent patient (Birnbaum et al., 2010). In contrast, adequate adherence to 
antidepressants has been associated with a reduction in overall medical costs (Cantrell, Eaddy, 
Shah, Regan, & Sokol, 2006). 
Adherence stands to be an important mechanism of outcome in pediatric psychiatry, 
especially given the frequent usage of psychiatric medications in youth along with low observed 
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adherence rates. As it stands already, unsuccessful treatment as a result of nonadherence burdens 
an already overtaxed mental health care system. Thus, increasing understanding of how children 
adhere to psychiatric medications can help individual patients, reduce financial costs to the 
medical system, and allow the mental health system to treat the millions of youths in need more 
effectively. Despite these wide ranging consequences, medication adherence in pediatric 
psychiatry remains an understudied variable (McGuinness & Worley, 2010). 
In considering variables that have traditionally affected adherence, a number of factors 
have emerged. With regard to physical factors, side effects of medication as well as convenience 
of administration predict adherence (Julius, Novitsky, & Dubin, 2009; Mitchell, 2006). 
Exemplars of these phenomena include patients who may find it easier to adhere to once-a-day 
medication dosing relative to multiple intradaily doses, and patients who experience greater side 
effects can sometimes reduce the amount of medication they are taking when they experience 
these undesired effects. Demographic factors also have relationships with adherence. Overall 
adherence is worse for children relative to adults (Costello, Wong, & Nunn, 2004) and in 
particular adolescents can show increased difficulties with adherence (Matsui, 2007). 
In addition to these factors, one unique aspect of adherence in pediatric psychiatry is that 
the pathology itself can reduce adherence (Smith & Shuchman, 2005). This is particularly 
impactful for child psychiatry, as a recursive process can exist where adherence to psychiatric 
intervention is reduced by psychopathology, and then this low adherence precludes 
improvements in psychopathology, which subsequently continues to impact adherence. For 
example, a depressed child may be less likely to be motivated to take medication, adhere more 
poorly, and remain more depressed as a product of this nonadherence, which subsequently 
continues to attenuate adherence as part of a vicious cycle. 
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Although physical, demographic, and psychopathology-related factors can affect 
adherence, they are not fully predictive of behavior, and at times provide only limited avenues 
for adherence improvement. However, other psychosocial variables provide a potential 
opportunity to improve adherence and merit further consideration, especially as significant 
variability has been observed among physicians with regard to their approaches to adherence 
(Drotar, 2009). One traditional approach has been defined as the health beliefs model, which 
focuses on the perceived benefits of medications in contrast to perceived harms (Rosenstock, 
1966). A related framework that has also been applied to adherence behavior is social cognitive 
theory, which focuses on expectations for positive outcomes and expectations for ability to 
complete adherence behavior (Bandura, 1998). Such approaches have been successful for 
increasing adherence and health-promoting behavior in a number of medical conditions, 
including asthma and heart disease (Bandura, 2004). Yet another approach to psychosocial 
variables in adherence has been the theory of planned behavior (TPB), which focuses on three 
components: patient attitudes towards adherence, patients’ perceived subjective norms towards 
adherence, and patient expectations about their ability to engage in adherence (Ajzen, 2011). The 
TPB model predicts engagement for a number of health behaviors, ranging from increases in 
exercise to reductions in risk-taking behavior (McEachan, Conner, Taylor, & Lawton, 2011). 
However, these traditional models suffer from some shortcomings. They were originally 
conceptualized in adults, and the complexity of these models is compounded in pediatric care as 
these variables can apply to both parents and children (Matsui, 2007). Also, while these 
traditional approaches have made some inroads into predicting adherence, much variance 
remains to be explained (Riekert, Ockene, & Pbert, 2013). They are further limited by their focus 
on patient-level behavior, neglecting patient-provider and family-based interactions (Clark & 
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Janevic, 2013). To address this limitation, models that incorporate the patient-provider 
interaction (such as therapeutic alliance) merit addressing in the context of adherence and 
outcome (Diamond, 2012). 
Considering the Role of Therapeutic Alliance in Pediatric Psychiatry 
 
The therapeutic alliance focuses on the interaction between patient and clinician, and in 
adults has been conceptualized in terms of three components: the bond between clinician and 
patient, agreement on the tasks to be completed in therapy, and agreement on the therapeutic 
goals to be achieved (Bordin, 1979). In children, these individual components have been 
identified as important, but at times have not emerged as separate factors, and instead a one-
factor model of alliance has been primarily found (Shirk, et al., 2011). Differences between adult 
and pediatric alliance models have arisen for a number of reasons, including distinct perspectives 
provided by children and the presence of multiple parties in therapy (e.g., parents and children; 
Zack, Castonguay, & Boswell, 2007). Children may also not have the cognitive capacity to 
differentiate task and goals (which are more cognitively based) from the bond (which is more 
emotionally based; Shirk & Karver, 2011). With regard to the process of alliance in child 
therapy, alliance formation involves the clinician simultaneously serving in a position of active 
listening while also providing a directive framework for treatment (Shirk, et al., 2011).  
The alliance has been highlighted most extensively in the psychotherapy literature, where 
it has shown a robust effect on treatment outcome across psychotherapies (Horvath, Del Re, 
Flückiger, & Symonds, 2011). Additionally, alliance can predict other important child therapy 
processes such as patient engagement and retention (Castro-Blanco & Karver, 2010; Garcia & 
Weisz, 2002). However, while the necessity of the physician-patient relationship has been 
identified as critical in adherence for overall pediatric practice (Winnick, Lucas, Hartman, & 
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Toll, 2005), it has received very little attention in child psychiatry despite the patient-provider 
relationship being central to establishing a diagnosis and to making a treatment prescription. 
Nevertheless, some empirical data has addressed the alliance in psychiatry. In adult 
depression, the average alliance throughout treatment accounts for 19% to 56% of variance in 
pharmacological treatment outcome (Krupnick et al., 1996; Weiss, Gaston, Propst, Wisebord, & 
Zicherman, 1997), and alliance can predict outcomes even when already accounting for 
technique effects from cognitive behavioral therapy (CBT) and/or antidepressant medication 
(Klein et al., 2003). Early alliance in treatment may be particularly predictive of antidepressant 
outcomes (Blatt & Zuroff, 2005). Alliance may also have a specific effect on medication 
outcome, as it has displayed differential effects between active compounds and placebo 
medication in SSRI treatment for depression (Strunk et al., 2010). Alliance and expectancies 
have also predicted adherence and outcome in pharmacotherapy for bipolar disorder (Gaudiano 
& Miller, 2006; Sylvia et al., 2013; Zeber et al., 2008) and in the usage of antipsychotic 
medication (Frank & Gunderson, 1990; McCabe et al., 2012). Alliance may affect other therapy 
process variables as well, as the odds of medical treatment adherence are 2.16 times greater 
overall if a physician is a good communicator (Zolnierek & DiMatteo, 2009). Thus, these limited 
data indicate that alliance is not only an accessory to psychiatric treatment, but may in fact drive 
a significant proportion the treatment process and subsequent outcome in pharmacotherapy. 
A number of reasons have been posited regarding why alliance may affect outcomes. One 
theory focuses on the sufficiency of strong alliance formation, which allows the patient to enact 
changes that might not otherwise be made alone (Norcross, 2010). In this context, the alliance is 
the principal stimulus that leads patients to identify and enact positive change as a result of 
therapy. Another aspect is that alliance helps patients engage in other therapy elements (De 
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Nadai, King, Karver, & Storch, 2014). Under this conceptualization, a strong alliance provides a 
foundation for communication in therapy that enhances patient engagement in specific 
techniques and interventions provided by the clinician, which then result in therapeutic change. 
Alliance has been found to be consistently related to adherence in a number of mental health 
treatments, and may work partially through improving expectancies for treatment (Thompson & 
McCabe, 2012). In psychiatry, it has been suggested that alliance can directly improve patient 
outcomes, and may also indirectly improve outcomes through its positive effects on adherence 
(Priebe & McCabe, 2008). However, this hypothesis remains understudied. No comparative data 
exist for children, though doctor-patient communication (an analogue of alliance) has been 
shown to predict adherence to a variety of pediatric medical treatments (DiMatteo, 2004). Child 
psychiatry also differs from traditional therapy with adults due to the dual importance of both 
child-clinician as well as parent-clinician alliance (Joshi, 2006), as child and parent alliance may 
have some orthogonal contributions to mental health outcomes (Bickman et al., 2012; Hawley & 
Weisz, 2005). While understudied, alliance affects both process and outcome variables in 
psychological and medical treatments. 
Considering the Role of Motivation for Behavior Change in Pediatric Psychiatry 
 
While patient motivation has been identified as a key principle in routine psychiatric 
practice (Chanut, Brown, & Dongier, 2005), its effects have been rarely quantified in 
pharmacotherapy for pediatric psychopathology. Motivation for behavior change in the context 
of psychopathology has most often been conceptualized in terms of the transtheoretical model 
for change, which posits that patients are often at different stages of readiness for change. This 
succession of stages include precontemplation (has not considered change), contemplation (has 
some desire to change, but also some desire to maintain the status quo and has not initiated 
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change), preparation (has started to take steps that lead to change), action (has initiated the 
change process), and maintenance (working to retain changes that have been made; Prochaska & 
DiClemente, 2005). Interventions tailored to specific stages of changes have displayed efficacy 
in changing behaviors ranging from smoking cessation to physical activity promotion (Cahill, 
Lancaster, & Green, 2010; Marshall et al., 2003), and while it was originally derived in the 
context of substance use disorders, the relationship between readiness for change and outcome in 
a number of psychotherapy approaches has been identified through meta-analysis (Norcross, 
Krebs, & Prochaska, 2011). The transtheoretical model has proven quite flexible, permitting for 
application to a wide range of behaviors (including exercise, domestic violence, and organ 
donation) and in a broad array of treatment settings, ranging from primary care to college 
campuses (Lundahl et al., 2013; Prochaska, Redding, & Evers, 2008).  
In considering pediatric psychiatry, parental motivation for change has been identified to 
predict adherence to psychiatric medication (De Nadai, 2013), and better outcomes have been 
found in pharmacotherapy for depressed adolescents who are in the action stage of change at 
baseline (Lewis et al., 2009). While data are limited with youth, higher levels of 
precontemplation have been associated with less change during pharmacotherapy for adults with 
obsessive compulsive disorder (OCD; Pinto, Pinto, Neziroglu, & Yaryura-Tobias, 2007). 
Unfortunately, stages of change research has received relatively little attention in psychiatry, 
despite the robustness of its supporting literature and its likely relevance for psychiatric research 
and practice (Cole, Bogenschutz, & Hungerford, 2011). Notably, psychiatric disorders often 
present barriers to motivation for change that prevent successful intervention for change in the 
disorder itself (Dilallo & Weiss, 2009), creating a self-sustaining barrier to symptom change. 
While patient motivation affects both distal patient symptom outcomes as well as proximal 
 12 
 
therapy process outcomes, the relative magnitude of its direct and indirect effects have rarely 
been quantified for any health condition, and it remains an understudied variable in pediatric 
psychiatric practice. 
Considering the Role of Expectancies in Pediatric Psychiatry 
 
Expectancies for psychiatric care can be distilled into two major aspects: what the patient 
expects his/her role to be in treatment (role expectancies) and what the patient expects for 
treatment outcome (outcome expectancies; Dew & Bickman, 2005; Glass, Arnkoff, & Shapiro, 
2001). Outcome expectancies have received particular focus in mental health treatments 
(Delsignore & Schnyder, 2007), and they have been identified to predict treatment outcomes in 
psychotherapy through meta-analysis (Constantino, Arnkoff, Glass, Ametrano, & Smith, 2011), 
including CBT for social phobia, fear of flying, and pediatric obsessive compulsive disorder 
(Lewin, Peris, Lindsey Bergman, McCracken, & Piacentini, 2011; Price, Anderson, Henrich, & 
Rothbaum, 2008; Safren, Heimberg, & Juster, 1997). Outcome expectancies do not exist in a 
therapeutic vacuum but rather work jointly with other common factors, as patients with positive 
treatment expectancies have been found to have stronger alliances (Connolly Gibbons et al., 
2003; Constantino, Arnow, Blasey, & Agras, 2005; Greenberg, Constantino, & Bruce, 2006; 
Hersoug, Hoglend, Havik, & Monsen, 2010) and adhere better to psychological treatments 
(Constantino, Ametrano, & Greenberg, 2012). This mechanistic relationship with alliance may 
be particularly strong, as Joyce et al. (2003) found that alliance could account for approximately 
one-third of the relationship between expectancies on outcome. Motivation for change has also 
been associated with outcome expectations (McKee et al., 2007), though expectancies are 
distinct from motivation, as patients may be motivated for change yet still not expect noteworthy 
positive changes from therapy (Arnkoff, Glass, & Shapiro, 2002). This construct distinction has 
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also been observed in pediatric psychotherapy, where parent outcome expectancies have been 
found to predict adherence above and beyond parent motivation for treatment (Nock, Ferriter, & 
Holmberg, 2006). 
Despite the wide ranging effects observed for psychological treatments, expectancies 
have received comparatively little attention in psychopharmacological interventions. With regard 
to extant data, adolescents’ outcome expectations for depression treatment have predicted 
outcomes across psychological and psychopharmacological modalities (Curry et al., 2006), and 
similar findings have been found in adult depression (Sotsky et al., 1991). Distinguishing 
patients with high and low expectations may provide a particularly stark contrast, as 90% of 
patients with strong expectancies showed treatment response in a single-blind trial of reboxetine 
for depression, in comparison to 33% of patients with low expectancies (Krell, Leuchter, 
Morgan, Cook, & Abrams, 2004). It has been argued that common factors account for a majority 
of variance in adult antidepressant therapy for depression, and in particular expectancies may be 
a central mechanism for this effect (Kirsch, 2013). Alliance has also been demonstrated as a 
mediating mechanism whereby expectancies exert outcome effects in pharmacotherapy for both 
unipolar and bipolar depression (Gaudiano & Miller, 2006; Meyer et al., 2002). In addition to 
these findings in depressive disorders, outcome expectancies along with perceived quality of 
clinicians’ explanations of medications have been related to adherence in ADHD treatment (e.g., 
Berger, Dor, Nevo, & Goldzweig, 2008; McNicholas, 2012).  
Troublingly, there may be lower expectations for primarily pharmacological approaches. 
Rapaport et al. (1996) found that when surveying depressed patients about possible sources of 
successful relief, medication alone was perceived as the least likely to help (8%), relative to 
talking therapy alone (25%) and combined medication and talk therapy (62%). Lax et al. (1992) 
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also found that patients with OCD had stronger treatment expectations for psychological 
treatment relative to pharmacotherapy, though expectations were strong for both treatment 
modalities. Expectancies may also impact trials of clinical compounds, as response rates are 
higher in antidepressant trials when the medication under evaluation is compared to another 
active medication as opposed to placebo (Rutherford, Sneed, & Roose, 2009). There are some 
data that indicate that this finding may be due to higher expectancies for symptom reduction, 
given that when patients are certain they are receiving active treatment they expect better 
outcomes, as opposed to placebo-controlled trials where patients are uncertain if they are 
receiving treatment that will be helpful (Rutherford, Sneed, Devanand, Eisenstadt, & Roose, 
2010). 
The powerful influence of outcome expectancies is well known in other areas of 
medicine. Indeed, many physicians attempt to capitalize on their effects - over half of surveyed 
physicians have reported that in the prior year, they have prescribed medications to raise patient 
expectations as opposed to using them primarily for their original intended therapeutic effects 
(Tilburt, Emanuel, Kaptchuk, Curlin, & Miller, 2008). There is some evidence that expectancy 
itself works through neural mechanisms that regulate the experience of emotion (Enck, 
Benedetti, & Schedlowski, 2008; Rutherford et al., 2010), and thus expectancy enhancing 
interventions (Constantino et al., 2012) are not completely independent from biological 
interventions. However, the role of outcome expectancies for medication therapy in pediatric 
psychiatry remains poorly understood, with regard to both direct treatment effects as well as 
indirect effects through variables such as adherence and alliance. 
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Considering the Influence of Alliance, Motivation, and Expectancies on Adherence in the 
Context of Outcome in Pediatric Psychiatry 
A conceptual model of how common factors can affect psychiatric outcomes can be 
found in Figure 1. This figure illustrates several notable facets. First, direct effects on outcome 
are expressed by separate constructs including alliance, motivation, and expectancies, which 
frequently have been amalgamated into a generic unitary placebo construct. Second, these 
common factors are addressed for both parents and children through multi-informant reporting, 
permitting comparisons among them. Third, mechanisms of effects are incorporated, with 
alliance and adherence both functioning as mediators of improved psychiatric outcomes. At 
present, while placebo effects have been identified to account for a substantial amount of 
outcomes in pharmacotherapy (Leucht, Hierl, Kissling, Dold, & Davis, 2012), few attempts have 
been made in the psychiatric literature to quantitatively break down the nature of these placebo 
effects. This limits treatment targeting, as the proportion of outcomes attributable to different 
common factors and different treatment participants has not been identified. This model also 
readily includes potential moderators. For example, adherence rates may well differ for children 
of different ages, given that parents often take more responsibility for medication administration 
for younger youth relative their older counterparts (Hsin, La Greca, Valenzuela, Moine, & 
Delamater, 2010). 
Implications of the Present Study 
 
While it is logical that psychosocial variables affect pediatric psychiatric treatment, the 
research base is sparse with regard to their effects on outcome. Accordingly, a number of 
important implications stand to follow from an empirical investigation of their mechanistic 
effects. Most directly, these factors are likely to be associated with improved psychiatric 
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outcomes, and highlighting their roles in a quantitative manner could lead to subsequent targeted 
interventions to improve relevant behavior. This process fosters personalized medicine as 
alliance, motivation, and expectancies could be measured via brief questionnaires during routine 
clinical care, and patients who have undesirable values on any of these metrics could receive a 
targeted intervention. At present such judgments (if made at all) are done through clinical 
judgment, which is an inferior process compared to evaluation by actuarial means (Dawes, 
2005). Currently, there exists little guidance beyond clinical intuition regarding how much 
difference these variables make in pharmacotherapy outcomes for mental disorders in children. 
Given that psychiatric drug development has lagged behind that of other medication classes 
(Cowen, 2011), this approach provides a new avenue for gains in symptom reduction, via 
adjustment of concurrent parameters of therapy. This approach has some parallel, as a number of 
advances in chemotherapy over the past 40 years have been made by adjusting the administration 
parameters of existing agents (Roberts & Thomas, 2005). In addition, an increased focus on 
common therapy factors could facilitate safety monitoring of these psychotropic agents, as 
improving the patient-provider relationship and patient motivation to engage actively in 
treatment could reduce acute discontinuation and foster communication channels for reporting of 
problems before they escalate. It also reintroduces the nature of therapy into psychiatric care, as 
a brief medication check has become established as a standard of care in pediatric psychiatry 
(Pruett, Joshi, & Martin, 2010).  
Additionally, these findings could be used to improve the training of medical providers. 
Strong alliances are not inherent to all clinician-patient relationships, and significant variability 
has been detected among therapists with regard to the quality of alliances (Del Re, Flückiger, 
Horvath, Symonds, & Wampold, 2012). Challenges also exist in maintaining professionalism 
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while also forming a strong individual relationship with patients (Priebe & McCabe, 2008), and 
tension or degradation in the therapeutic relationship (known as “ruptures”) in the alliance can 
impair treatment. However, alliance ruptures also provide the opportunity for skillful clinicians 
who repair such ruptures in psychotherapy to obtain particularly strong clinical outcomes 
(Safran, Muran, & Eubanks-Carter, 2011). In this context, a number of psychosocial 
interventions have been designed to improve adherence in pediatrics, which often focus on CBT 
and/or motivational interviewing (MI) techniques (Dean, Walters, & Hall, 2010; Haynes, 
Ackloo, Sahota, McDonald, & Yao, 2008). These interventions can be delivered by allied 
providers for both psychiatric and non-psychiatric conditions (e.g., Rubio-Valera et al., 2011). 
There is evidence that MI can be successfully taught to medical providers, resulting in changes in 
physician behavior and enhanced patient outcomes (Soderlund, Madson, Rubak, & Nilsen, 
2011). Specific training to improve alliances with psychiatric medication providers has also 
improved both adherence and outcome to psychotropic medication interventions in adults (Byrne 
& Deane, 2011), and expectancy enhancement manuals could also be adapted for child 
psychiatry. The effects of clinician skills have been shown in psychiatric treatment, as one study 
has found that a positive response to pharmacotherapy was only seen by patients who had a 
clinician who was a skilled communicator (van Os et al., 2005). Still, the research base is limited 
with regard to physician-patient communication in psychiatry, to which the present study can 
contribute. 
Data generated from this investigation can also highlight mechanisms of outcome, as 
little is known about the process by which the common factors and the placebo process operate 
in pediatric psychiatry. Given that placebo and common factor effects can account for a 
significant proportion of pharmacotherapy outcomes, the field currently has a lack of knowledge 
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about precisely why a number of medications are effective (e.g., SSRIs; Fernandez & Gaspar, 
2012). It has been questioned whether the clinician-patient relationship is an adjuvant that fosters 
the implementation of active medications, or whether it provides an additive effect above and 
beyond pharmacotherapy (Priebe & McCabe, 2008). The present study is the first in pediatric 
psychiatry to separate effects due to pharmacotherapy and effects due to common factors 
elements. 
Results from this investigation may also affect the practice of subsequent research. Poor 
adherence to psychiatric medication can be a common confound in the results of clinical trials 
(Case, 2011), reducing the ability to accurately identify the degree of symptom change due to 
medication administration and possibly attenuating efficacy estimates. In another context, a 
medication may have a large effect, but if the common factors also have large effects, the 
observed effects of the medication may be washed out in a between-groups comparison. These 
data would provide an initial metric to estimate how much common factors influence should be 
observed when planning clinical trials. 
The purpose of this study is to evaluate the role of psychosocial variables in pediatric 
psychiatric practice. It was hypothesized that stronger motivation, expectancies, alliances, and 
adherence would be associated with reductions in psychiatric symptoms. Specifically, it was 
predicted that these psychosocial variables would work in tandem, with pretreatment 
expectancies and motivation being predictive of stronger alliances, which would be predictive of 
stronger adherence and subsequent outcomes. Understanding psychosocial mechanisms of 
outcome in pediatric psychiatry highlights a way forward to improve future clinical care, and 
provides a framework to help understand the assumptions underlying prior research. While 
medication is often attributed as the active intervention in pediatric psychiatric practice, this 
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study proposes to reframe contemporary psychiatric practice and partition outcomes into a 
variety of meaningful components. This investigation stands to open up for consideration 
significant changes to clinical practice, future research, and the training of medical providers. 
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Method 
Participants 
Participants were 159 youth ages 7-17 years presenting for psychiatric treatment 
(M=11.79, SD=3.10), along with their parents and treating clinicians. Participants were 42.1% 
female, and the ethnic/racial distribution was 78.6% Caucasian, 1.9% African American, 7.5% 
Hispanic, 0.6% Pacific Islander, 0.6% as Middle Eastern, 10.1% identifying as “other,” and 0.6% 
not providing information on race/ethnicity. Participants were recruited from one of three sites: 
The USF Silver Center for Child Development (USF; n=65), the All Children’s Hospital 
Pediatric Psychiatry Clinic (ACH n=63), and the Rothman Center for Pediatric Neuropsychiatry 
(RCN n=31). The USF and ACH sites are not-for-profit outpatient clinics that serve youth with a 
broad array of psychiatric problems, while the RCN site is a non-profit specialty clinic that 
focuses on pediatric OCD and related conditions (e.g., anxiety disorders, tic disorders).  
Participating patients were recruited from those referred to board-certified psychiatrists or 
supervised child and adolescent psychiatry fellows for care as usual, with no circumscribed limit 
on the number of patients seen per individual provider. Through the normal course of care, 
clinical diagnoses were established through a clinical interview utilizing all available 
information, as recommended by Klein, Dougherty, and Olino (2005) as well as Silverman and 
Ollendick (2005). To add further support for diagnoses, a clinical level of symptomology as 
indicated by either child or parent via self-report (on the MASC-ADI, CDI-2-SF, YSR, or 
CBCL) was used as a requirement for study inclusion using a diagnostic “or” rule (Piacentini, 
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Cohen, & Cohen, 1992). No identifiable data collected from participating youth and 
parents regarding alliance, motivation, expectancies, or adherence was shared with 
participating clinicians.  
Prescriptions were provided by study clinicians to 127 participants, and a total of 
231 observations were available for analysis (1.57 medications prescribed per participant 
who received medication). Common types of medications provided included stimulants 
(n=56), serotonin reuptake inhibitors (n=58), alpha-2 agonists (n=24), and atypical 
antipsychotics (n=17). Common diagnoses assigned to participants included externalizing 
(n=40), internalizing (n=94), neurodevelopmental (n=38), ADHD (n=87), and tic 
disorders (n=23). Regarding other interventions received, 39.8% of those who responded 
to 1-month follow-up calls reported receiving concurrent treatment from another provider 
by that timepoint, and 52.9% of respondents who responded to 3-month follow-up calls 
reported receiving concurrent treatment from another provider by that timepoint. 
Procedures 
After obtaining informed consent, measures pertaining to questionnaires on 
motivation and expectancies were completed before participants’ scheduled initial 
clinical visit, and questionnaires related to alliance were completed immediately after the 
clinical session. At one and three months after the initial study intake session, study 
participants received follow-up assessments via phone. A timetable indicating the 
timepoint at which each self-report measure was administered (baseline, 1-month follow-
up, or 3-month follow-up) can be found in Table 1. 
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Measures 
All study measures free of non-redistributive copyright can be found in Appendices A-K. 
Parent and child rated measures. 
University of Rhode Island Change Assessment (URICA; McConnaughy et al., 1983). 
The URICA is a 32-item measure of motivation for behavior change in mental health treatment. 
Items are rated on a 5-point Likert scale ranging from “strongly disagree” to “strongly agree.” 
The URICA has four subscales (precontemplation, contemplation, action, and maintenance), and 
the URICA total score is calculated by subtracting the precontemplation subscale from the sum 
of the contemplation, action, and maintenance subscales. Higher scores reflect greater readiness 
for behavior change. Modification of the URICA for different populations is encouraged (Rossi, 
1995) and such modification has been successfully employed in other studies (e.g., Dozois, 
Westra, Collins, Fung, & Garry, 2004; Greenstein, Franklin, & McGuffin, 1999). In the present 
investigation, minor modifications were made to certain relevant items (e.g., changing the word 
“psychology” to “psychiatry”) on both parent and child forms to properly address their role in 
treatment. The child form focuses on child readiness for change, and the parent form also focuses 
on readiness for child behavior change (e.g., what is their perception of the child’s problem, are 
parents contemplating the concept that their child needs to change). Similar modifications have 
displayed acceptable internal consistency in youth ages 7-17 years (alpha=.71; Keeley, Geffken, 
Ricketts, McNamara, & Storch, unpublished data), as well as in adults (alpha=.79; Dozois et al., 
2004). Pretreatment child URICA scores have been shown to be associated with higher 
pretreatment child anxiety reported via the MASC (r=.33, Keeley et al., unpublished data), and 
have been observed to predict positive outcomes in adult psychotherapy (Norcross, Krebs, & 
Prochaska, 2011). 
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Clinician rated measures. 
Therapeutic Alliance Quality Rating (TAQ-R; Bickman et al., 2010). The TAQ-
R is a standardized clinician rating of therapeutic alliance with other treatment parties 
(i.e., parents and children). It consists of a 1-item rating for the perceived alliance with 
each therapeutic party that asks, “In this session, how would you describe your 
relationship with this youth/caregiver.” The TAQ-R is rated on a 5-point Likert scale with 
responses ranging from “very poor” to “excellent.” In the development of the TAQ-R, an 
initial item pool of 52 items was generated to address the bond, task, and goals elements 
of therapeutic alliance as specified by Bordin (1979), though it was determined through 
item response theory and classical psychometrics that single item TAQ-R ratings 
provided largely redundant information for clinician-rated alliance (Bickman et al., 
2010). Variability in TAQ-R scores has been observed for both clinician ratings of 
alliance with the parent (M=4.22, SD=0.71) and youth (M=3.80, SD=0.82) in a large 
clinical sample (Bickman, et al., 2010), and TAQ-R scores have been found to be 
predictive of treatment outcome (Bickman, et al., 2012). 
Parent rated measures. 
Working Alliance Inventory-Short Form (WAI-SF; Horvath & Greenberg, 
1989; Tracey & Kokotovic, 1989). The WAI-SF is a parent-rated measure of therapeutic 
alliance with the treating clinician. It was originally designed to measure therapeutic 
alliance in adult psychotherapy, and has been successfully adapted to assess therapeutic 
alliance of parents of children in psychotherapy (Hawley & Garland, 2008). It consists of 
12 items rated on a 1-7 Likert scale ranging from “never” to “always,” and focuses on 
parental agreement on the tasks to be performed in their child’s treatment, parental 
 24 
 
agreement with the clinician on the goals of their child’s treatment, and the therapeutic bond 
between parent and clinician. When used with parents of children in psychotherapy, it has 
demonstrated acceptable internal consistency and test-retest reliability (alpha>.93, 6-month test-
retest r=.77; Hawley & Garland, 2008) and has predicted improvements in youth 
psychopathology and parent satisfaction during psychosocial treatment (Hawley & Garland, 
2008). 
Credibility/Expectancy Questionnaire-Parent Version (CEQ-P; Nock, Ferriter, & 
Holmberg, 2006). The CEQ-P is a measure of parental outcome expectations and treatment 
credibility. It consists of 6 items, with factor analysis supporting a two-factor model of 3 items 
each (falling along the lines of treatment credibility and expectancies). The present study 
employs the expectancy subscale of the CEQ-P, which has demonstrated strong internal 
consistency (alpha=.88) and adequate test-retest reliability after 6-8 sessions of psychotherapy 
(r=.52; Nock, et al., 2006). Scores on the CEQ-P have been associated with parent motivation to 
participate in treatment, and the CEQ-P expectancy subscale has correlated with parental 
treatment adherence in pediatric psychotherapy (Nock, et al., 2006). 
Child Behavior Checklist (CBCL; Achenbach & Rescorla, 2001). The CBCL is a 
parent-report measure of internalizing and externalizing symptoms in children over the past six 
months. It consists of 118 items rated on a 0-2 Likert scale ranging from “not true” to “very 
true,” and total scores are computed for overall internalizing and externalizing behavior. Based 
on a normative sample, internal consistency has been observed to be .90, .94, and .97 for the 
internalizing, externalizing, and total scores, respectively (as measured by Cronbach’s alpha), 
and eight day test-retest reliability has been observed at .91, .92, and .94 for the internalizing, 
externalizing, and total scores, respectively (Achenbach & Rescorla, 2001). A t-score of 60 or 
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above has been found to differentiate youths based on treatment referral status, where 
treatment referral status can be determined with 85% accuracy on the CBCL (Achenbach 
& Rescorla, 2001). 
Brief Progress Monitor-Parent Version (BPM-P; Achenbach, McConaughy, 
Ivanova, & Rescorla, 2011). The BPM-P is a measure designed to track changes in child 
psychopathology throughout treatment. It includes 19 parent-rated items that are scored 
on the same 0-2 Likert scale as the CBCL. It evaluates internalizing and externalizing 
psychopathology as well as symptoms of inattentiveness, and consists of a subset of items 
from the Child Behavior Checklist (Achenbach & Rescorla, 2001) that were identified 
via factor analysis with the intention of providing a brief, reliable, and valid measure of 
symptom tracking over time. Internal consistency (as measured by Cronbach’s alpha) has 
been observed to be .80, .85, .88, and .92, for the internalizing, inattentiveness, 
externalizing, and total scores, respectively (Achenbach, McConaughy, Ivanova, & 
Rescorla, 2011). Eight day test-retest reliability has been observed to range from .81 to 
.85 for each of these scores, and the total score has been shown to effectively identify the 
presence of a psychiatric diagnosis and the use of mental health services in the prior year 
(Tarren-Sweeney, 2013). 
Brief Medication Questionnaire (BMQ; Svarstad, Chewning, Sleath, & 
Claesson, 1999). The BMQ is a parent-rated measure of adherence to pharmacotherapy. 
The 7-item medication regimen screen portion of the BMQ was employed via phone 
follow-up. Brief Medication Questionnaire items have shown test-retest stability (Rickles 
& Svarstad, 2007), have correlated with adherence measurement via electronic 
monitoring (Shi et al., 2010), and have been used successfully to evaluate psychiatric 
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medication administration with pediatric caregivers (Dean, Wragg, Draper, & McDermott, 
2011). Percentage of medication adherence over the prior week can be calculated following 
procedures described by Curtin, Keller, and Svarstad (1999), which consist of dividing the 
number of doses missed over the past week by the number of prescribed doses indicated for the 
week, and then subtracting this value from 1. 
Service Assessment for Children and Adolescents (SACA; Stiffman et al., 2000). The 
SACA is a measure of service utilization in children and adolescents. In its original form, it 
consists of 30 items administered via parent interview. It has demonstrated excellent agreement 
in service utilization measurement when compared to service records (kappa=.76; Hoagwood et 
al., 2000), and it is frequently modified to match specific patient populations while maintaining 
reliability and validity (Stiffman et al., 2005). To reduce participant burden, a 13-item version 
was used in the present investigation, which combines items regarding outpatient, inpatient, and 
community-based services while still covering all relevant services received. 
Frequency, Intensity, and Burden of Side Effects Rating/Patient Rated Inventory of 
Side Effects (FIBSER/PRISE; Wisniewski et al., 2006). The PRISE is a checklist of side effects 
experienced during pharmacotherapy, and the FIBSER is a rating of the frequency, intensity, and 
burden of side effects experienced from taking psychiatric medication. The PRISE (a 9-item 
presence/absence checklist) is used to highlight relevant side effects before the administration of 
the FIBSER (a 3-item measure rated on a 0-6 Likert scale). The FIBSER has demonstrated 
strong internal consistency (alpha=.91-.93), and higher scores on the FIBSER have been 
associated with treatment dropout in a randomized controlled trial for adult depression 
(Wisniewski, Rush, Balasubramani, Trivedi, & Nierenberg, 2006). The FIBSER and PRISE were 
originally designed for use with adults. They were modified to be used by parents to evaluate 
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their child’s side effects for the present investigation; items have been inspected by a 
board-certified child and adolescent psychiatrist (Dr. Mark Cavitt at the ACH study site) 
to ensure item appropriateness for the study population.  
Child rated measures. 
Therapeutic Alliance Scale for Children-Revised (TASC-R; Shirk & Saiz, 
1992). The TASC-R is a measure of youth therapeutic alliance in treatment. Its 12 items 
are rated on a 4-point Likert scale and assesses bond with the clinician and agreement 
with the clinician on therapeutic tasks. The TASC-R provides minor wording 
modifications to the original TASC so that it can address therapeutic alliance at a specific 
treatment session, whereas the original TASC measures alliance across multiple sessions 
(Creed & Kendall, 2005). Internal consistency of the TASC-R has been demonstrated for 
children ages 7-17 (alpha=.88-.92; Creed & Kendall, 2005; Keeley, Geffken, Ricketts, 
McNamara, & Storch, 2011). Acceptable levels of test-retest reliability have been 
observed over a period of five psychotherapy sessions (r=.60; Keeley et al., unpublished 
data), and TASC-R scores at session 5 have predicted treatment outcome in CBT for 
pediatric OCD (Keeley et al., 2011).  
Credibility/Expectancy Questionnaire-Child Version (CEQ-C). The CEQ-C is a 
child-rated assessment of outcome expectancies and treatment credibility. Its 6 items 
were designed to parallel items on the adult CEQ (Devilly & Borkovec, 2000). It was 
created for the present investigation due to the lack of empirically validated measures of 
treatment expectancies for youth. The CEQ was originally developed as a modification to 
the Expectancies Rating Questionnaire (ERQ; Borkovec & Nau, 1972) to reduce 
confounding with treatment credibility observed in the ERQ. Similar content is shared 
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among the measures, and the ERQ has been successfully used with youth ages 7 years and above 
(Ollendick et al., 2009), suggesting appropriateness of item content for children. The present 
study employs the expectancy subscale of the CEQ-C, which has three items that are rated on 
either a 9- or 11-point Likert scale. When used with adults, this subscale has been observed to 
have adequate internal consistency (alpha=79-.90), with a 1-week test-retest reliability value of 
r=.82 (Devilly & Borkovec, 2000). The two-factor structure has been supported in adults by 
confirmatory factor analysis, and expectancy subscale scores have been correlated with 
reductions in anxiety and global distress during treatment for adult anxiety (Devilly & Borkovec, 
2000).  
Youth Self Report (YSR; Achenbach & Rescorla, 2001). The YSR is a child-report 
measure of internalizing and externalizing behavioral problems in children that is intended to 
parallel the CBCL. It consists of 112 items rated on a 0-2 Likert scale ranging from “not true” to 
“very true or often true,” resulting in total scores for overall internalizing and externalizing 
behavior. While originally designed for youths ages 11-17, the YSR has demonstrated strong 
internal consistency for youth ages 7 and above, with Cronbach’s alpha values of .88-.89, .88-
.89, and .93 observed for the internalizing, externalizing, and total problems scales respectively 
(Ebesutani, Bernstein, Martinez, Chorpita, & Weisz, 2011). A t-score of 60 or above has been 
found to differentiate youths based on clinical referral status (Achenbach & Rescorla, 2001). 
Items focusing on drug use and sexual behavior were not included, as it was not necessary to 
expose younger participants to these items for the purposes of the present investigation, and 
adjustments to YSR drug use items have been successfully employed in other investigations 
(e.g., Substance Abuse and Mental Health Services Administration, 1999).  
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Multidimensional Anxiety Scale for Children-Anxiety Disorders Index (MASC-
ADI; March, Parker, Sullivan, Stallings, & Conners, 1997). The MASC-ADI is brief 
measure of anxiety symptomology in children. It consists of 10 items rated on a 0-4 scale 
that ranges from “never true about me” to “often true about me.” These items are a subset 
of items from the 39-item MASC that were identified to best discriminate children with 
anxiety disorders from nonclinical control participants. Psychometric adequacy has been 
demonstrated with children ages 7-17 years, with an observed internal consistency of 
alpha=.74 (Grills-Taquechel, Ollendick, & Fisak, 2008) and three month test-retest 
reliability of r=.70 (March, Parker, Sullivan, Stallings, & Conners, 1997). When used as 
a screening instrument to differentiate anxious children from nonclinical controls, the 
MASC-ADI has displayed sensitivity values of .90-.95, specificity values of .84-.95, an 
overall correct classification rate of 87-95%, and kappa values of .74-.90 (March, 1997). 
The MASC-ADI has also been able to distinguish children with anxiety disorders from 
nonclinical controls when using discriminant function analyses (Grills-Taquechel et al., 
2008; Rynn et al., 2006).  
Children’s Depression Inventory-2nd Edition Short Form (CDI-2-SF; Kovacs, 
2011). The CDI-2-SF is a child-rated measure of depressive symptoms intended for 
children ages 7-17 that was empirically derived from the 28 item CDI-2 long form. Its 10 
items are rated on a 0-2 scale and cover the affective, cognitive, and neurovegetative 
aspects of pediatric depression, and a total score is produced to quantify overall severity 
of depression. Internal consistency for the CDI-2-SF has been observed at alpha=.82, its 
two week test-retest reliability has been indicated to be r=.77, and it is strongly correlated 
with the CDI-2 long form (r=.95, p<.001; Kovacs, 2011). The CDI-2-SF has displayed 
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sensitivity and specificity values of .84 and .77, respectively, when used to differentiate children 
meeting DSM-IV criteria for major depressive disorder from matched controls (Kovacs, 2011). 
For predicting clinician diagnosis, Kovacs (2011) recommends the CDI-2-SF in lieu of the 
complete CDI, as it has displayed stronger psychometric properties for this purpose than the full 
CDI-2 form (e.g., better test-retest reliability, better discriminant validity, and improved 
sensitivity and specificity when using a clinical cutoff score of 6).  
Analytic Plan 
The present study design reflected multiple levels of nesting. Because multiple 
medications were allowed for each patient at each timepoint, there were multiple observations 
per timepoint, multiple timepoints per patient, multiple patients per clinician, and multiple 
clinicians per site. To identify if method-based adjustments for nested data clustering were 
necessary, design effects for all dependent variables were considered, where design effects 
greater than 2 reflect a need to adjust estimates for clustering (Muthén & Satorra, 1995). Among 
nesting variables (i.e., time, participant, clinician, and site), design effects were greater than 2 
only for clinician and site. To address nesting by clinicians, the MLR-complex estimator was 
employed for all analyses, with clinician specified as the clustering variable. To address nesting 
by site, dependent variables in all analyses were predicted by dummy-coded site variables before 
adding predictors and covariates, reflecting a fixed effects approach to clustering (as specified by 
Cohen, Cohen, West, & Aiken, 2003). The distribution of adherence was nonnormal, with 
disproportionate amounts of patients displaying either very low or very high adherence. This 
nonnormality was addressed by use of the MLR-complex estimator.  
All bivariate relationships tested as a part of study hypotheses are displayed in Figure 1. 
Figure 1 shows a pattern of effects that reflect expectancies and motivation as pretreatment 
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factors, which then affect subsequent alliance; alliance then affects adherence, and adherence 
then affects treatment outcome. Relationships among variables that were not modeled as 
unidirectional causes of one another were defined as exogenous, while endogenous relationships 
were defined when variables were determined by other variables in the system. Relationships 
among exogenous variables were evaluated by correlational methods, while relationships 
between exogenous and endogenous variables were evaluated by regression methods. 
Correlations tested were partial correlations (i.e., correlating the residuals after partialing out the 
effects of site out of each variable, in order to account for site-based clustering). Regressions 
were evaluated by first regressing dependent variables onto dummy-coded site, and then adding 
hypothesized predictors to this model. To evaluate prediction of treatment outcome, 3-month 
BPM-P scores were first regressed on both site and baseline scores, and then hypothesized 
predictors were added to this model, reflecting a residualized regression. Outcomes were 
considered separately for each BPM-P subscale (Internalizing, Externalizing, Attention 
Problems). 
Moderation of bivariate regressions was also considered, with the effects of each 
individual moderator evaluated in separate models. Moderators included type of medication 
(including stimulants, SRIs, atypical antipsychotics, alpha-2 agonists, and a comparison was also 
made between patients who received medication at all and those who did not), disorder class 
(including internalizing, externalizing, neurodevelopmental, ADHD, and tic-related disorders), 
patient age, concurrent treatment as reported at 1- and 3-month follow-up, and respective 
FIBSER items corresponding to frequency, intensity, and interference associated with side 
effects. Medications were classified based on category definitions established in the Federal 
Drug Administration National Drug Code Directory (Federal Drug Administration, 2017). 
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Disorders were classified based on suggestions in the DSM-5 (American Psychiatric Association, 
2013), which notes that a series of papers commissioned by Andrews (2009) shaped 
classification schemes and provided further information regarding the rationale for 
categorization. When the Andrews (2009) papers disagreed with final DSM-5 classification, 
disorders in question were evaluated in their own class. This affected ADHD (which is 
considered with neurodevelopmental disorders in DSM-5, but shows strong relationships with 
externalizing disorders both conceptually and in the Andrews, 2009 papers) and tic disorders 
(which were unclassified in the Andrews, 2009 papers and show limited phenomenological 
overlap with other disorder classes evaluated in this study). Moderators were evaluated in 
analyses if they were observed more than 15 times in the study sample in order to accommodate 
central limit theory assumptions (Smith & Wells, 2006). Moderation models were computed by 
adding the moderator and its product with the main effect to regression models; significant 
moderation was evaluated based on the product term. All dichotomous moderators were dummy-
coded, and all continuous predictors were centered prior to creating moderator product terms 
used in models. To evaluate the results of statistically significant moderation, simple slopes were 
evaluated following procedures delineated by Preacher, Curran, & Bauer (2006). Simple slopes 
were evaluated at low, medium, and high levels of study moderators (with medium levels 
reflecting the mean of the moderator and low and high levels reflecting ±1 SD, or only with 0 
and 1 reflecting low and high levels respectively for dummy-coded moderators). Because 
moderators reflect post-hoc hypotheses, a Holm-Bonferroni correction (Holm, 1979) was used 
on all moderation analyses to determine statistical significance. This correction limits familywise 
Type I error while retaining more power than the traditional Bonferroni correction. As 
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recommended by Fairchild and McQuillin (2010), significance of simple slopes was tested via 
unstandardized coefficients. Standardized coefficients are reported to facilitate interpretation. 
Figure 1 also implies mediation-based relationships. Indirect effects were tested for all 
variables that showed significant a and b paths in main effect and/or moderated models (e.g., if 
alliance significantly predicted adherence and then adherence significantly predicted outcomes in 
separate bivariate models). Significant direct effects were not required to consider a test of 
moderation given that a number of processes can lead to significant indirect effects in the 
absence of direct effects (Hayes, 2013). Moderators that were significant after Holm-Bonferroni 
correction were also included in respective indirect models (which reflects a process of 
moderated mediation; please see Figure 2 for a visual depiction of modeled indirect paths). 
Simple slopes in moderated mediation models were evaluated following procedures delineated 
by Hayes (2013), and Mplus implementations of these procedures provided by Stride, Gardner, 
Catley, and Thomas (2015) were employed when available. These procedures focus on 
evaluating the significance of the product of the indirect paths (i.e., ab for a single moderator or 
abc for 2 sequential moderators), and also take into account the direct effect of X on Y (c’). 
Standard errors for tests of indirect effects were calculated based on the delta method. As with 
other analyses, site-based clustering was accounted for by including dummy-coded site variables 
on all DVs in indirect effect models. Inconsistent mediation was observed when the indirect 
effect had the opposite sign of direct effects (MacKinnon, Fairchild, & Fritz, 2007). 
With respect to effect sizes, small, medium, and large effect sizes respectively apply to 
partial correlations of .1, .3, and .5, and regression model R2 values of .01, .09, and .25 (Cohen, 
1988). For main effects in regression models, R2 was evaluated based on the amount of variance 
a main effect accounted for above and beyond site (defined as ME-R2 for main effects) and for 
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moderators, R2 was evaluated based on how much variance was explained by adding the 
moderator and the moderator product term to the main effect model (defined as ΔR2). Effect 
sizes reported for indirect effects were based on recommendations by Wen and Fan (2015) to 
report standardized estimates of the indirect, direct effect, and total effects. To illustrate, Wen 
and Fan (2015) provided an example based on standardized estimates, where if the indirect effect 
is 0.2, the direct effect is 0.3, and the total effect is 0.5, then it can be interpreted that for a 
change of 1 standard deviation in X, Y will change 0.5 standard deviations, of which 0.2 
standard deviations are attributable to the indirect effect and 0.3 standard deviations are 
attributable to the direct effect. Regarding measure reliability, internal consistency was evaluated 
through the use of Cronbach’s alpha (Cronbach, 1951), with alpha values of .70 or higher 
considered acceptable (Nunnally, 1978). 
Data were missing at a rate of 26.4% on all variables modeled in Figure 1. The principal 
contributor to these missing data was follow-up response rate, as 52.2% of participants 
participated in 1-month follow-up and 53.5% of participants participated in 3-month follow-up. 
In addition, 20 youths among participating families (12.6%) did not provide assent to 
participation, for reasons including parents not wanting to add additional work to children during 
a clinic visit (n=4), children preferring to engage in other activity instead of participating (n=3), 
child/parent expressing concern that the child would be able to comprehend the self-report 
assessments (n=6), and 7 families did not provide a specific reason for choosing not to provide 
child assent. In cases of parental consent but lack of child assent, parents were willing to 
continue to provide behavioral data from themselves, but no child report was provided. To 
address missing data, several measures were taken. All hypothesis tests were estimated using 
full-information maximum likelihood estimation in Mplus version 7 (Muthén & Muthén, 2012). 
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Auxiliary variables were used to aid in the estimation of missing data via a saturated correlates 
model; auxiliary variables included all common factors as rated by parents, children, and 
clinicians, as well as baseline scores on all BPM-P subscales. The effects of clinician and site 
were also included as auxiliary variables in all models (as a part of accounting for their clustering 
effects in all models). Means and variances of all predictors and covariates were also estimated 
via FIML estimation (as opposed to assumed as fixed) to aid in parameter estimation in the 
presence of missing data. 
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Results 
Descriptive Variable Characteristics and Relationships Among Exogenous Variables 
Descriptive statistics for the present sample can be found in Table 2; internal consistency 
for all measures was acceptable. Correlations among exogenous study variables can be found in 
Table 3. Among pretreatment exogenous variables, child motivation (via the URICA-C) was 
significantly correlated with all other pretreatment exogenous variables, including the CEQ-C 
(partial r=0.34, p=.002), the CEQ-P (partial r=0.16, p=.031), and the URICA-P (partial r=0.23, 
p=.006). Regarding relationships among alliance reporters, clinician-reported alliance with 
parents was significantly related with parent-rated alliance (via the WAI-SF; partial r=0.26, 
p<.001) and clinicians’ ratings of their alliance with participating children (via the TAQ-R-P; 
partial r=0.26, p=.008). Additionally, clinician ratings of their alliance with children was 
significantly correlated with child ratings of alliance (via the WAI-SF; partial r=0.47, p<.001). 
The correlation among adherence measurements at follow-up at 1-month and 3-months was also 
significant (partial r=0.55, p<.001). 
Bivariate Predictive Relationships 
Bivariate predictive relationships for all main effects and significant moderators of main 
effects can be found in Table 4. 
Prediction of alliance by motivation and expectancies. Child-rated alliance showed a 
significant relationship with child motivation (b=0.52, p<.001, ME-R2=.24). Child-rated alliance 
had a significant relationship with child expectancies and parental motivation, though these 
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effects varied in the presence of moderators. Child expectancies predicted child alliance for 
youth without ADHD (b=0.62, p<.001, ME-R2=0.08, ΔR2=0.15). It also predicted child alliance 
for youth on alpha-2 agonists, though it showed a positive relationship for youth who were not 
on these medications (b=0.31, p<.001, ME-R2=0.08, ΔR2=0.16) and a negative relationship for 
youth who received them (b=-0.02, p<.001, ME-R2=0.08, ΔR2=0.15). It also only predicted child 
alliance for youth who had low (b=1.03, p<.001, ME-R2=0.08, ΔR2=0.26) and medium (b=0.36, 
p<.001, ME-R2=0.08, ΔR2=0.26) intensity of side effects. Child alliance was also predicted by 
parent motivation, but showed a varying relationship based on concurrent treatment received 
during the 3 months post-baseline; youth who did not receive concurrent treatment during this 
time period showed a negative relationship between child alliance and parent motivation (b=-
0.26, p<.001, ME-R2=0.01, ΔR2=0.12), while those who did receive concurrent treatment 
showed a positive relationship between these variables (b=0.18, p=.012, ME-R2=0.01, 
ΔR2=0.12). Parent-rated alliance was significantly predicted by parental expectancies (b=0.22, 
p=.034, ME-R2=0.05) and parent motivation (b=0.30, p<.001, ME-R2=0.09). It was also 
predicted by child motivation, but only for youth who were prescribed atypical antipsychotics 
(where it had a negative relationship for these youth; b=-0.21, p<.001, ME-R2=0.00, ΔR2=0.05). 
Among pretreatment exogenous variables, the only one that significantly predicted 
clinician-rated alliance with children was child motivation (b=0.21, p=.014, ME-R2=0.04). With 
regard to predicting clinician-rated alliance with parents, child and parent motivation were found 
to be significant predictors of clinician-rated alliance with parents, though both of these effects 
were found to be moderated. The effect of child motivation on TAQ-R-P scores was moderated 
by prescription of atypical antipsychotics, with a stronger relationship for youth who were not 
prescribed these medications (b=0.27, p=.005, ME-R2=0.04, ΔR2=0.09), though a significant 
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positive relationship was also found for youth who received these medications (b=0.03, p<.001, 
ME-R2=0.04, ΔR2=0.09). The effects of parent motivation on TAQ-R-P scores were moderated 
by externalizing diagnosis; a negative relationship between motivation and alliance was found 
for youth without externalizing diagnoses (b=-0.22, p=.021, ME-R2=0.02, ΔR2=0.10), whereas a 
positive relationship was found for those who did have an externalizing diagnosis (b=0.22, 
p<.001, ME-R2=0.02, ΔR2=0.10). Child and parent expectancies were not significantly related 
with clinician-rated alliance with parents. 
Prediction of medication adherence by motivation, expectancies, and alliance. At 1-
month follow-up, medication adherence was negatively associated with parental expectancies 
(b=-0.34, p<.001, ME-R2=0.11) and child motivation (b=-0.28, p=.029, ME-R2=0.07). It also 
exhibited a positive relationship with clinician-rated alliance with children for participants who 
were prescribed atypical antipsychotics (b=0.14, p<.001, ME-R2=0.00, ΔR2=0.05). All other 
psychosocial variables were nonsignificant predictors of medication adherence at 1-month 
follow-up. The only significant predictor of medication adherence at 3-month follow up was 
parent expectancies, which was again associated with lower adherence (b=-0.19, p=.014, ME-
R2=0.05). 
Prediction of treatment outcome by adherence, motivation, expectancies, alliance, 
and medication adherence. With regard to predicting change in externalizing symptoms, all 
significant predictors of BPM-P Externalizing scores reflected a worsening of symptoms. This 
included child expectancies for youth with tic disorders (b=0.04, p<.019, ME-R2=0.01, 
ΔR2=0.06), child motivation for youth with tic disorders (b=0.14, p<.001, ME-R2=0.00, 
ΔR2=0.09), and parent alliance for youth who did not have externalizing disorders (b=0.40, 
p<.001, ME-R2=0.01, ΔR2=0.03). 
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With regard to predicting change in internalizing symptoms, clinician-rated alliance with 
parents was associated with a reduction in symptoms for youth prescribed atypical antipsychotics 
(b=-0.20, p<.001, ME-R2=0.00, ΔR2=0.06). An increase in internalizing symptoms was 
associated with higher levels of child motivation (b=0.27, p<.001, ME-R2=0.06), child 
expectancies for youth who were prescribed atypical antipsychotics (b=0.13, p<.001, ME-
R2=0.00, ΔR2=0.04), and those prescribed alpha agonists who had higher levels of medication 
adherence at 1-month follow-up (b=0.83, p<.001, ME-R2=0.03, ΔR2=0.07). Higher parent 
motivation was associated with internalizing symptom reduction in youth who did not receive a 
prescription at all (b=-0.18, p=.023, ME-R2=0.00, ΔR2=0.04), but symptom increases in youth 
who did receive a prescription (relative to no prescription at all; b=0.08, p<.001, ME-R2=0.00, 
ΔR2=0.04). Higher child alliance was associated with internalizing symptom reduction in youth 
who did not receive a prescription of atypical antipsychotics (b=-0.22, p=.019, ME-R2=0.02, 
ΔR2=0.09), but symptom increases in youth who were prescribed atypical antipsychotics 
(b=0.03, p<.001, ME-R2=0.02, ΔR2=0.09).  
With regard to predicting change in attention problems, a reduction in attention problems 
was associated with child alliance (b=-0.15, p=.047, ME-R2=0.02) as well as parent expectancies 
for children who experienced side effects at medium (b=-0.24, p<.001, ME-R2=0.07, ΔR2=0.18) 
and high (b=-0.77, p<.001, ME-R2=0.07, ΔR2=0.18) levels of intensity. Worsening of attention 
problems was seen for higher levels of clinician-rated alliance with parents for children who had 
not received concurrent treatment by 3-month follow-up (b=0.42, p<.001, ME-R2=0.00, 
ΔR2=0.04). 
Relationships of common factors with change in attention problems varied at different 
levels of moderators. Higher parent alliance was associated with a reduction in attention 
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problems for children who experienced low levels of functional interference due to side effects 
(b=-0.54, p=.002, ME-R2=0.02, ΔR2=0.20), but a worsening of symptoms for youth who 
experienced high levels of functional interference due to side effects (b=0.75, p<.001, ME-
R2=0.02, ΔR2=0.20) and youth who had received concurrent treatment at 3-month follow-up 
(b=0.35, p<.001, ME-R2=0.02, ΔR2=0.16). Additionally, greater adherence at 1-month follow-up 
was associated with a reduction in attention problems for youth with low intensity of side effects 
(b=-0.49, p=.015, ME-R2=0.01, ΔR2=0.17), but an increase in symptoms for youth with high 
intensity of side effects (b=0.61, p<.001, ME-R2=0.01, ΔR2=0.17).  
Indirect Predictive Relationships (Mediation) 
Results from analyses of therapeutic processes can be seen in Table 5, which correspond 
to the models depicted in Figure 2. With regard to the process externalizing symptom change, 
child motivation had an indirect influence on symptom reduction through parent alliance for 
youth prescribed atypical antipsychotics (ab=-0.48, p=.013). Inconsistent mediation was 
observed in this case for children who had tic disorders (i.e., the direct effect was associated with 
an increase in symptoms for children with tic disorders whereas the indirect effect was associated 
with a decrease in symptoms; c’=1.11, p<.001). Parent motivation was also indirectly associated 
through parent alliance with an increase in externalizing symptoms for children who did not have 
an externalizing diagnosis (ab=0.18, p=.010) 
With regard to the process of influence of internalizing symptom change, multiple 
expectancy factors showed an indirect effect on change through alliance. In particular, the effect 
of child expectancies on change in internalizing symptoms through child alliance varied 
depending on moderators. Child expectancies were associated with a worsening of symptoms for 
youth who were prescribed atypical antipsychotics but did not have an ADHD diagnosis 
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(ab=0.59, p<.001). In the context of youth with either/or prescriptions of alpha-2 agonistics or 
atypical antipsychotics, higher child expectancies were associated with a worsening of symptoms 
for youth who were prescribed either alpha-2 agonists (ab=0.26, p=.016) or atypical 
antipsychotics (ab=0.28, p=.012), but not for youth who were prescribed both of these 
medications simultaneously (ab=-0.96, p=.061) or who were not prescribed either of these 
medications (ab=-0.07, p=.079). The indirect effect of child expectancies on internalizing 
symptom change through child alliance also differed for youth prescribed atypical antipsychotics 
in the context of side effect intensity. Higher child expectancies through child alliance were 
associated with symptom reduction for children who were not prescribed atypical antipsychotics 
and had either a low (ab=-0.24, p=.015) or medium intensity of side effects (ab=-0.11, p=.018), 
but were associated with a worsening of symptoms for youth who did received these medications 
and also experienced either low (ab=0.80, p=.010) or medium (ab=0.36, p=.030) intensity of side 
effects.  
Motivation also had multiple indirect effects on internalizing symptom outcome. Child 
motivation indirectly predicted through child alliance an improvement of internalizing symptoms 
for children who were not prescribed atypical antipsychotics (ab=-0.31, p=.004); however, 
inconsistent mediation was found in this case as the direct effect of child motivation was 
associated with a worsening of internalizing symptoms (c’=0.57, p<.001). Parent motivation also 
predicted internalizing symptoms through clinician-rated alliance with parents; a worsening of 
symptoms was seen for youth who were prescribed atypical antipsychotics and did not have an 
externalizing diagnosis (ab=0.29, p=.005), but a reduction of symptoms was observed for 
children who received these medications and did have an internalizing diagnosis (ab=-0.50, 
p=.004).  
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Adherence also served as a mediator of treatment process variable effects on internalizing 
symptoms. Better internalizing outcomes were observed for youth who were prescribed alpha-2 
agonists and who also had higher parent expectancies (ab=-2.55, p=.001) and higher child 
motivation (ab=-2.75, p=.029). This latter effect reflected inconsistent mediation, as the direct 
effect of child motivation on internalizing symptom change through adherence was associated 
with a worsening of symptoms (c’=0.47, p=.001). Clinician-rated alliance with children was also 
indirectly associated through 1-month adherence with a worsening of symptoms for youth who 
were prescribed both atypical antipsychotics and alpha-2 agonists (ab=6.31, p=.016). 
With regard to the process of influence of attention problems, multiple expectancy and 
motivation factors showed an indirect effect on change through alliance. Worsening of 
symptoms was predicted by higher child expectancies through child alliance for youth who were 
prescribed alpha-2 agonists (ab=0.21, p=.042). Higher parent expectancies were associated with 
attention problem exacerbation directly through parent alliance for youth who received 
concurrent treatment by 1-month follow-up (ab=0.25, p=.029); however, these symptoms were 
inconsistent with direct effect symptom reductions for youth who had medium (c’=-0.53, 
p<.001) and high (c’=-1.05, p<.001) intensity levels of side effects. Higher levels of parent 
motivation were associated with worsening of attention problems indirectly through child 
alliance for youth who were prescribed stimulants (ab=0.05, p=.049) and indirectly thorough 
parent alliance for youth who received concurrent treatment by 1-month follow-up (ab=0.39, 
p<.001) and who had high levels of functional interference due to side effects (ab=0.30, p=.001). 
Parent motivation was also associated with worsening of attention systems indirectly thorough 
clinician-rated alliance with parents for youth who had an externalizing diagnosis and did not 
receive concurrent treatment by 3-month follow-up (ab=0.32, p=.002).  
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The indirect effect of child motivation on attention problems varied depending on 
moderators. For youth who were prescribed atypical antipsychotics, increased child motivation 
was associated with an increase in attention problems indirectly through parent alliance in youth 
with low levels of functional interference due to side effects (ab=0.35, p=.029) and a reduction 
in attention problems in youth who had high levels of functional interference due to side effects 
(ab=-0.66, p<.001). It was also associated with an indirect reduction of attention problems 
through parent alliance for youth who were prescribed antipsychotics and received concurrent 
treatment by 1-month follow-up (ab=-0.93, p<.001). For youth who did not receive concurrent 
treatment by 3-month follow-up, it was associated through clinician-reported alliance with 
parents with an exacerbation of symptoms for youth who were not prescribed atypical 
antipsychotics (ab=0.27, p=.015), though this reflected inconsistent mediation relative to the 
direct effect (c’=-0.39, p=.037), and also a reduction of symptoms for these youth was observed 
when they were prescribed atypical antipsychotics (ab=-0.49, p=.002). Adherence also served as 
a mediator of treatment process effects on attention problems, as clinician-rated alliance with 
children through 1-month adherence was indirectly associated with an increase in attention 
symptoms for youth prescribed atypical antipsychotics and who experienced a high intensity of 
side effects (ab=0.63, p=.023). 
The pattern of significance in bivariate analyses also resulted in one mediation model that 
had 2 mediators in sequence, which is depicted in Figure 2. From this model, child motivation 
showed an indirect effect through both clinician-reported alliance with children and adherence at 
1-month follow-up; this indirect effect depended on prescription of atypical antipsychotics and 
intensity of side effects. For youth with high intensity of side effects, a reduction in attention 
problems was observed when youth were not prescribed atypical antipsychotics (abc=-0.12, 
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p=.039), but an increase in attention problems was observed when atypical antipsychotics were 
prescribed (abc=0.13, p=.015). 
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Discussion 
The objective of this study was to examine the role of psychosocial variables in pediatric 
psychiatric treatment, including pretreatment expectancies, motivation for behavior change, 
therapeutic alliance, and medication adherence. It was anticipated that these variables would 
have positive relationships with each other and would be associated with symptom reduction. 
While the psychosocial variables largely showed positive relationships with each other, there 
were some unexpected inverse relationships, and there were many unexpected associations 
between psychosocial variables and exacerbated clinical symptoms. 
The main theme that encompasses the pattern of observed effects is that they were far 
less uniform than is usually reported in common factors literature. Usually, common factors are 
construed as single entities that only show positive relationships with each other and treatment 
outcome. While this pattern was observed at times, in the present investigation common factors 
were observed to function in different manners across populations, reporters, and interventions, 
frequently in a counterintuitive manner. These results suggest that common factors are not as 
theoretically consistent as is often portrayed in the mental health literature. Or, they may not be 
as theoretically consistent in child psychiatry as they are in other behavioral and medical fields. 
Psychosocial correlates of treatment outcome are underexplored in primarily psychiatric settings, 
which gives little basis for comparison. In pediatric psychotherapy, treatment process variables 
have been observed to show differing roles across treatment approaches (Hogue et al., 2006; 
Karver et al., 2008), and perhaps their function may differ even more markedly when 
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considering psychiatric approaches. It may also be that negative associations with common 
factors in other studies are weaker than the positive ones (as was observed in the Shirk et al., 
2011 meta-analysis for child alliance). In this case, these negative effects may exist, but even 
then they will be detected and reported less frequently. Given the novel approach of this study 
and the preliminary nature of its findings, its major contributions are less focused on individual 
findings. Instead, its primary value lies in highlighting that psychosocial variables have a notable 
impact on psychopharmacological treatment outcome in children, identifying that their influence 
may be much more complicated than is commonly portrayed, and identifying hypotheses for the 
origins of this complexity. 
Despite the observed inconsistencies, a number of patterns emerged among results that 
can be placed in context with prior literature. Regarding exogenous variables, significant 
correlations were all observed in the expected positive directions. Of note, the majority of 
nonsignificant correlations reflected cross-informant correlations (i.e., nonsignificant correlations 
were almost always those between a child-related construct and a parent-related construct). The 
only exception to this pattern was the nonsignificant correlation between parental motivation and 
parental expectancies. This disagreement across reporters has been well documented in pediatric 
mental health research (Martel, Markon, & Smith, 2016) and thus may reflect differences in 
reporter perspectives in addition to lack of construct overlap. With regard to expectancies and 
motivation, the most consistent correlate was child motivation, as more motivated children also 
had higher expectancies and had parents who had higher motivation and expected better 
treatment outcome. Child motivation is an underexplored construct, as the majority of motivation 
research in child psychopathology focuses on parental motivation. These findings suggest that it 
may not only be related to outcomes, but also may serve as a unique indicator of positive ratings 
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on other psychosocial constructs. One exception to the observed pattern of correlations was that 
that parent motivation and parental expectancies were not significantly correlated. While adult 
motivation and expectancies are often related, there are reports of nonsignificant relationships 
among the constructs (e.g., Vogel et al., 2006). The magnitude of the observed correlation was 
similar to other significant correlations in this study, reflecting an effect of measurement error on 
the detection of a significant relationship. 
Several patterns also emerged in predictive models, which applied to bivariate 
approaches as well as moderated and mediated approaches. A very surprising pattern was the 
multiple associations of therapeutic alliance with an increase in symptoms; a common thread 
among many of these observations is that such worsening occurred only in the presence of 
markers of externalizing behavior (e.g., prescription of medications that are used for 
externalizing conditions such as alpha-2 agonists or atypical antipsychotics). Although alliance is 
usually associated with improved treatment outcome, with these patients early session alliance 
has been associated at times with an increase of symptoms in psychotherapy (Florsheim, 
Shotorbani, Guest-Warnick, Barratt, & Hwang, 2000; Hogue, Dauber, Stambaugh, Cecero, & 
Liddle, 2006). Others have observed that some of these patients may actually need more clinician 
authority and boundary setting early on in the therapeutic relationship (Gallagher, Kurtz, & 
Blackwell, 2010). Different therapist engagement behaviors can be differentially effective 
depending on the treatment approach (Karver et al., 2008), and youth with externalizing behavior 
are an identifiable target population for using modified engagement techniques (Karver & 
Caporino, 2010). Additionally, some of these patients may be adept at positive self-presentation 
for a limited period of time early in treatment, which may be a marker for poorer outcome 
(Florsheim et al., 2000). An ideal therapeutic relationship in early sessions may then differ for 
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these patients, as warmth and emotional support may be more appropriate for patients who are 
less likely to test clinician boundaries, while an authoritative but empathic early relationship may 
set the stage for better outcomes for patients who may be more likely to initiate discord. The 
unexpected relationships between alliance and outcome for these patients was also reflected in 
observed negative indirect effects, as any positive effects of expectancies/motivation on outcome 
were reversed when communicated through a negative relationship between alliance and 
outcome. This indirect effect was observed despite positive direct effects at times (e.g., a positive 
direct effect of child motivation on symptom reduction), leading to inconsistent mediation. This 
pattern of moderation was also seen in prediction of alliance, as alliance more frequently had a 
positive relationship with other common factors for patients who did not match the 
externalizing/ADHD profile. 
Similarly surprising was the frequently negative association between higher expectancies 
and treatment outcome. While expectancies have often been associated with positive treatment 
outcome, there has been more variability in the relationship between expectancies and treatment 
relative to other common factors (Greenberg et al., 2006). In addition, overly high expectancies 
can be associated with poorer treatment overcome should treatment response not match these 
high standards of expectations (Constantino et al., 2011; Gaitan-Sierra & Hyland, 2015). 
Accordingly, clinicians may wish to carefully monitor not only the overall level of expectancies, 
but also consider whether they are appropriate given the expected outcomes.  
Another unexpected result was the pattern of relationships observed with adherence. A 
limited and confounded set of relationships were detected between adherence and other common 
factors as well as treatment outcome, as opposed to the uniformly positive associations expected. 
Most remarkably, stronger adherence was at times associated with poorer outcomes. However, 
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this was generally in the presence of stronger side effects or medications for youth with 
externalizing problems, whereas youth with fewer side effects more frequently showed a positive 
relationship between stronger adherence and positive treatment outcome. It may be that if 
medications are aversive, adhering to them strongly actually does not help outcome and may be 
making matters worse in the long run. In this case, monitoring side effects is not just a factor in 
premature medication discontinuation (Julius et al., 2009) but is also a possible reason for 
suboptimal outcomes, even in patients who are taking medications appropriately. Yet, given the 
strong role of adherence in outcome for a number of conditions, it was still unanticipated that 
adherence would not be significantly related with outcome or other common factors in many 
instances.  
Additionally, when considering relationships between other common factors and 
adherence, parent expectancies and child motivation were associated with poorer adherence. 
Only clinician-rated alliance with children was associated with better medication adherence, and 
in this case only for youth who were prescribed atypical antipsychotics. While overly optimistic 
expectancies may have the same deleterious effects on adherence as they can on outcome, the 
relationship between adherence and motivation cannot be explained in the same fashion. Of note, 
motivation was assessed in the context of motivation for making personal changes in 
symptomology, not motivation for adherence (which at times has been considered a separate 
construct; Touré-Tillery & Fishbach, 2014). Children who may be looking to make active 
behavioral steps toward change may eventually get there, but may find medications to be a less 
active means to achieve this end (as has been seen in some patient preference studies; e.g., 
Angelo, Miller, Zoellner, & Feeny, 2008). Given that child motivation was also related to parent 
expectancies, children who are more motivated to make active changes themselves may have 
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parents who are overly expectant of change. Moreover, they may also function better with more 
active methods of change, and may find a pharmacologically-based intervention to be 
inconsistent with their preferred approach to change.  
In contrast to these unpredicted findings, child motivation was more frequently associated 
with symptom improvement. This is more consistent with the overall common factors literature. 
In some ways, motivation differs from other common factors with reference to theoretical 
relationships with treatment outcome and patterns of moderation. Unlike expectancies, 
motivation is unlikely to show negative effects on outcome when it is too high. Motivation 
differs from alliance with regard to moderation, as the nature of an appropriate alliance may 
differ across internalizing and externalizing populations (Zorzella, Muller, & Cribbie, 2015), 
whereas the function of motivation is more stable across these groups. For instance, pure warmth 
for an internalizing patient may serve as enabling for an externalizing patient, whereas the nature 
of patient motivation does not vary in this between-population manner. Instead, within-
population variability is more likely to differ across disorders, as internalizing patients are more 
often self-referring for treatment and less likely to show poor motivation for change (e.g., Duhig 
& Phares, 2003). Less within-population variability would also be expected for parents, given 
that they are frequently the ones who make the decision about whether to initiate child treatment 
(Nock & Kazdin, 2001). Thus by default parents have motivation for child behavior change, 
leaving more room for variability in children. This decreased variability in parental motivation 
may reduce the ability to predict outcomes of interest. Given these facets of parent and child 
motivation, child motivation appears to be a common factor that is uniquely indicative of future 
symptom reduction, compared to parent motivation which is less variable. 
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Notably, several hypothesized moderators did not significantly interact with main effects. 
In particular, significant moderation was not observed for child age and for variables associated 
with internalizing and neurodevelopmental disorders (including clinician diagnoses of these 
conditions and prescription of SRIs). While nonsignificance does not mean that these variables 
do not have an effect on observed relationships, and post-hoc correction reduces the power to 
detect their specific influence, it does reflect that they had a lesser influence on the common 
factors process relative to other moderators. It may be that common factors show a more 
consistent effect in the presence of these constructs. While there have been some suggestions of 
developmental differences in the presentation of therapeutic alliance in particular (Shirk, 
Caporino, & Karver, 2010), the nature of common factors may vary more substantially among 
youth who are less likely to desire treatment themselves (i.e., children with 
disruptive/externalizing problems). Frequency of side effects also did not significantly moderate 
outcomes, while intensity and functional interference associated with side effects were 
significant moderators. Frequency of symptoms has a different and possibly more limited 
relationship with mental health symptoms than intensity and functional interference, as patients 
may have one especially impairing symptom which is very bothersome, or conversely may 
experience multiple low level symptoms that in aggregate are not very bothersome (Jones et al., 
2013). Often in these cases overall symptom severity (as rated by perceived intensity and/or 
interference) is of greater importance.  
With regard to overall magnitude of findings, most significant results in bivariate 
analyses were in the medium range, which is consistent with meta-analytic estimates of common 
factors in psychotherapy. Several standardized indirect effects also particularly stood out relative 
to the others (larger than 2), all of which involved the role of 1-month adherence for youth who 
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were prescribed alpha-2 agonists and the associated effects on internalizing symptoms. The 
strong effect of this b path was the common element among these indirect effects. It may be that 
effects of adherence are particularly pronounced for youth taking alpha-2 agonists, where in this 
instance increased adherence was associated with worsening of internalizing symptoms. Alpha-2 
agonists were notable among study medications in that they have uniquely strong effects of acute 
withdrawal, as rebound hypertension and distress can occur within even one day of sudden 
discontinuation (particularly with clonidine; Giovannitti, Thoms, & Crawford, 2015). The 
distribution of adherence in study participants approximated bimodality, especially for poor 
adherence; that is, patients who had low adherence had generally stopped prescribed medications 
altogether, while patients who took medication showed more variability in adherence. While 
strong but imperfect adherence may be adequate for many medications, required adherence 
levels may be even higher for alpha-2 agonists, and inconsistent adherence to these medications 
may be associated with an increase in internal emotional distress. Standard errors for these 
estimates were fairly large as well, resulting in p-values that were not as small as many other 
significant effects observed. Given this, the size of these indirect estimates may have been 
affected in part by instability associated with the relatively relative small sample size of youth 
prescribed alpha-2 agonists in the present sample.  
As a whole, the observed patterns of results (and their exceptions) merit replication and 
evaluation in future research. As such, it is premature to make strong and conclusive inferences 
from individual findings, but rather the present models suggest new hypotheses that have often 
not been considered in common factors research (e.g., alliance being associated with increases in 
symptoms under some conditions, common factors having heterogeneous effects across 
conditions and interventions). Additional possible reasons for the observed exceptions could 
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include confounding variables that were unaccounted for (Moore, Neugebauer, van der Laan, & 
Tager, 2012). For instance, there is some evidence of reciprocal influence of alliance and 
symptom change in pediatric psychological treatment (Labouliere, Reyes, Shirk, & Karver, 
2015) and this longitudinal influence may confound results observed at 3 months after treatment 
initiation. Oppositional youths in particular may show more instability in the therapeutic 
relationship throughout the course of treatment (Rauktis, Vides de Andrade, Doucette, 
McDonough, & Reinhart, 2005). While initial status of psychosocial variables frequently has a 
substantial influence on subsequent treatment outcome, perhaps consideration of their continued 
role throughout treatment can serve to further explain the observed results in future research. 
This concept would be reflected in part by the relative lack of prediction of 3-month adherence 
relative to the more robust set of associations with 1-month adherence. Perhaps pretreatment 
common factors are more strongly related to more proximal outcomes and as the outcomes 
become increasingly distal, changes in psychosocial variables show a more dynamic influence 
(e.g., alliance ruptures; Safran & Kraus, 2014). 
Several limitations of this study are to be noted. First, there were missing data at all time 
points, with a substantial amount of missing data at follow-up timepoints in particular. Multiple 
efforts were made to address this missingness that have been shown to produce substantial 
improvement in parameter estimation in real-world research (e.g., FIML estimation, including 
auxiliary covariates that are predictive of missingness). Such methods can produce estimates that 
match population parameters. These missing data were a trade-off for obtaining a naturalistic 
sample that resembles treatment-seeking patients from a variety of backgrounds. Other studies 
with real-world populations have been successfully conducted with even higher levels of missing 
data by using similar analytical approaches (Dong & Peng, 2013). Second, given that inclusion 
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criteria were very broad with treatment-seeking patients, there is substantial heterogeneity in 
psychopathology and psychopharmacology among participants. Common factors have generally 
been seen to have influence across populations, but rarely are they evaluated in a sample that is 
representative of such a broad set of problems. This broad sample permitted comparisons of the 
role of common factors across these populations and allowed for the generation of a number of 
unforeseen findings, which would be not be possible with more limited inclusion criteria. 
Nevertheless, this heterogeneity, along with lack of randomization, precludes the identification 
of causal mechanisms and a priori evaluation of differences across populations. This study is a 
first step towards evaluating the role of multiple psychosocial variables in tandem with 
psychopharmacological intervention, and as such serves as both a test of prior hypotheses and as 
a means to generate new ones for further investigation. Third, measurement of symptom change 
was restricted to self-report, and there was not a single best outcome measure for each patient. 
Future work would benefit from independent evaluation of diagnosis and symptom severity. 
With multiple measures of outcome (i.e., externalizing, internalizing, attention problems), this 
study is able to capture the different targets of treatment relevant to each patient. One concern 
about using these multiple measures of outcome is that symptom measurements were included 
for non-principal treatment targets (e.g., measuring internalizing symptoms in a child with 
ADHD and few internalizing problems). While the analytic models employed adjust estimates 
for pre-treatment scores, this process can serve to reduce the average magnitude of change. 
However, there were many participants with externalizing, internalizing, and attention problem 
symptoms, providing sufficient variability to evaluate symptom change outcomes for these 
domains. This method is consistent with other studies in pediatric psychopathology, which 
frequently eschew a single total combined total score and rather divide behavior problems into 
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subgroups such as internalizing and externalizing symptoms (Lindhiem, Bennett, Orimoto, & 
Kolko, 2016). Symptom increases in non-principal treatment targets are also possible and often 
are overlooked in clinical work, and this multi-domain approach to outcome measurement 
permitted evaluation of this hypothesis. Finally, a large number of hypothesis tests were 
performed. Post-hoc hypotheses involving moderators were controlled using strong post-hoc 
corrections, but the chance for Type I error still remains. 
Clinically, these results suggest that common factors impact treatment outcome, even in 
psychopharmacological interventions. While they show notable influence across a number of 
populations, their impact may not be as straightforward as is often portrayed. There may not be a 
single “optimal patient” who receives better outcomes due to intrinsic motivation, a positive 
outlook towards treatment, and strong alliance with the clinician. In fact, being too strong in 
some of these areas may actually attenuate outcome in some circumstances. Moreover, the 
process of how these factors work concurrently throughout treatment may also be 
counterintuitive at times. Changes in the function of common factors during the full course of 
treatment has also been seen in psychotherapy; for example, early alliance may be facilitated by 
warmth and empathy, whereas alliance later on in treatment may be better developed by 
directiveness for patients who are looking for continued change (Keijsers et al., 1995). For these 
reasons, careful monitoring of both the level and specific role of common factors throughout 
treatment is warranted. One option to implement this type monitoring is through brief 
assessments in therapy progress notes (De Nadai et al., 2017). In pediatric interventions, the 
presence of multiple therapeutic stakeholders means this monitoring involves several 
dimensions, as parents, children, and clinicians often do not agree on common factors (e.g., 
Bickman et al., 2012). Monitoring of therapeutic alliance for children with ADHD and 
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externalizing disorders may deserve special focus. A positive initial alliance can be associated 
with poorer long-term outcomes for these patients, which is contrary to conventional wisdom. 
Theoretically, these results suggest that psychosocial variables serve as common factors 
across patient populations and treatment interventions in pediatric psychiatry, but the nature of 
their influence on outcome may not be as common as originally thought. They are generally 
considered to have a consistently positive impact on symptom outcome and are conceptualized in 
this manner across all symptom types and patient populations. While not frequently considered, 
possible symptom exacerbations based on psychological interventions have been overlooked 
(Barlow, 2010). Not only are the effects of psychosocial variables not uniformly common across 
situations, but they may not be common across reporters as well. Contradictory effects were 
observed at times depending on the reporter in the present sample. Reporting agreement in child 
mental health treatment is often highly variable further examination among reporter agreement 
and discrepancies may provide further insight (De Los Reyes et al., 2015). Methods that unify 
the input of multiple reporting parties such as the Alliance Observational Coding System 
(AOCS, Karver, Shirk, Day, Field, & Handelsman, 2003) or factor analytic modeling (Bauer et 
al., 2013) may also provide novel insight regarding how common factors function within child 
common factors research. 
Results from this investigation suggest that the process of how common factors work 
together can lead to unexpected changes in results. Many investigations focus on the early 
session role of common factors or aggregate measures of common factors throughout treatment, 
and rarely do they go beyond bivariate associations with outcome. Given how the function of 
psychosocial variables can change throughout treatment, continual measurement of these 
variables in clinical investigations may be necessary to elucidate their effects. For example, 
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interpersonal processes between clinician and patient have predicted subsequent outcome 
expectancies even when controlling for baseline differences in expectancies (Ahmed, Westra, 
and Constantino, 2012), and dyadic reciprocity in alliance has been observed in adult patients 
(Marcus, Kashy, Wintersteen, & Diamond, 2011). How common factors vary among each other 
and across time will be necessary to understand their role in treatment outcome. 
Overall, the impact of psychosocial variables spans across pediatric psychiatric 
treatments, but may not function in a “one size fits all” fashion across different therapeutic 
populations and approaches. The present findings suggest that the process of how common 
factors work in pediatric psychiatry may be much more complicated than is often suggested. 
Psychosocial variables can cut across treatments as elements that are common to all psychiatric 
interventions, but the nature of their effects on outcome may actually not be common. Careful 
consideration of the differences in roles of psychosocial variables across patient populations and 
interventions may help to better explain treatment effects in clinical and research settings, with 
particular focus on how they are impacting treatment for both better and worse. 
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Tables and Figures 
 
Table 1. Timetable of self-report assessments administered 
 
 Baseline M1 M3 
Parent    
Parent Alliance (WAI-SF) X   
Parent Expectancy (CEQ-P) X   
Parent Motivation (URICA-P) X   
Parent-Reported Adherence (BMQ)  X  
Parent-Rated Symptoms (CBCL) X   
Parent-Reported Outcome (BPM-P) X  X 
Parent Report of Services (SACA)  X X 
Parent-Rated Side Effects (FIBSER/PRISE)  X  
Youth    
Youth Alliance (TASC-R) X   
Youth Expectancy (CEQ-C) X   
Youth Motivation (URICA-C)    
Youth Anxiety and Depression (MASC-ADI/CDI-2-SF)a X   
Youth Symptoms (YSR)a X   
Clinician    
Clinician Alliance (TAQ-R) X 
  
Note. M1=1-month follow-up; M3=3-month follow-up; WAI-SF=Working Alliance Inventory-
Short Form; CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; URICA-P= 
University of Rhode Island Change Assessment-Parent Version; BMQ=Brief Medication 
Questionnaire; CBCL=Child Behavior Checklist; BPM-P=Brief Progress Monitor-Parent 
Version; SACA= Service Assessment for Children and Adolescents; FIBSER=Frequency, 
Intensity, and Burden of Side Effects Rating; PRISE=Patient Rated Inventory of Side Effects; 
TASC-R=Therapeutic Alliance Scale for Children-Revised; CEQ-C=Credibility/Expectancy 
Questionnaire-Child Version; URICA-C= University of Rhode Island Change Assessment-Child 
Version; MASC-ADI=Multidimensional Anxiety Scale for Children-Anxiety Disorders Index; 
CDI-2-SF=Children’s Depression Inventory-2nd Edition Short Form;  
YSR=Youth Self Report; TAQ-R=Therapeutic Alliance Quality Rating 
 
aThe MASC-ADI and CDI-2-SF were administered to 21 participants who had anxiety and/or 
depression diagnoses; all other participants received the YSR 
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Table 2. Descriptive statistics for the present sample 
 
Variable Mean SD Alpha 
CEQ-C 16.62 5.94 .84 
CEQ-P 17.16 4.83 .85 
URICA-C 7.70 2.58 .87 
URICA-P 10.36 1.29 .71 
TASC-R 37.77 6.94 .86 
WAI-SF 71.61 9.67 .90 
TAQ-R-Child 3.57 0.70 N/A 
TAQ-R-Parent 3.98 0.68 N/A 
MASC-ADIa 14.50 6.21 .75 
CDI-2-SFa 5.95 3.76 .74 
CBCL Externalizing 15.98 10.80 .92 
CBCL Internalizing 16.43 9.39 .87 
YSR Externalizinga 20.76 9.50 .88 
YSR Internalizinga 21.19 11.75 .90 
BMQ (M1) 70.25 42.15 N/Ab 
BMQ (M3) 68.14 44.47 N/Ab 
FIBSER-Frequency 2.33 2.25 N/Ab 
FIBSER-Intensity 1.98 1.67 N/Ab 
FIBSER-Interference 1.33 1.52 N/A
b 
BPM-P Externalizing (Baseline) 5.81 3.47 .82 
BPM-P Externalizing (M3) 5.16 3.58 .86 
BPM-P Internalizing (Baseline) 4.52 2.92 .76 
BPM-P Internalizing (M3) 5.06 3.28 .81 
BPM-P Attention Problems (Baseline) 6.86 3.25 .81 
BPM-P Attention Problems (M3) 5.98 3.37 .83 
Note. M1=1-month follow-up; M3=3-month follow-up; CEQ-C=Credibility/Expectancy Questionnaire-
Child Version; CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; URICA-C= University of 
Rhode Island Change Assessment-Child Version; URICA-P= University of Rhode Island Change 
Assessment-Parent Version; TASC-R=Therapeutic Alliance Scale for Children-Revised; WAI-
SF=Working Alliance Inventory-Short Form; TAQ-R=Therapeutic Alliance Quality Rating; MASC-
ADI=Multidimensional Anxiety Scale for Children-Anxiety Disorders Index; CDI-2-SF=Children’s 
Depression Inventory-2nd Edition Short Form; CBCL=Child Behavior Checklist; YSR=Youth Self 
Report; BMQ=Brief Medication Questionnaire; FIBSER=Frequency, Intensity, and Burden of Side 
Effects Rating; BPM-P=Brief Progress Monitor-Parent Version 
 
a
The MASC-ADI and CDI-2-SF were administered to 21 participants who had anxiety and/or depression 
diagnoses; all other participants received the YSR 
 
bCronbach’s alpha could not be calculated for this measure because only one item is used to create the 
total score 
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Table 3. Bivariate correlations among psychosocial variables 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1. CEQ-C - 0.07 0.34** 0.03 0.27** 0.11 0.08 0.10 -0.08 -0.12 0.06 0.11 0.16 0.12 -0.16 0.10 -0.02 -0.09 0.05 
2. CEQ-P - - 0.16* 0.17 0.17 0.22* 0.13 0.04 -0.30 -0.26** -0.24 -0.33** -0.32** -0.10 0.05 -0.09 -0.20 -0.10 -0.32** 
3. URICA-C - - - 0.23** 0.49** -0.05 0.21* 0.19* -0.24 0.03 0.03 -0.11 -0.02 -0.09 0.18* -0.06 -0.13 0.34** -0.19 
4. URICA-P - - - - 0.06 0.30** -0.06 0.14* 0.22 0.11 0.08 0.25 0.29** 0.08 0.18* -0.04 0.09 0.12 0.02 
5. TASC-R - - - - - -0.01 0.47** 0.12 -0.07 0.10 0.08 -0.21* -0.34** -0.07 -0.18** 0.05 -0.13 -0.23* -0.11 
6. WAI-SF - - - - - - 0.01 0.26** 0.00 -0.03 0.08 0.15 0.31** 0.02 0.08 0.05 0.11 0.10 0.17 
7. TAQ-R-C - - - - - - - 0.26** -0.09 -0.10 0.29* -0.07 -0.17 -0.26* -0.09 -0.14 -0.03 -0.08 -0.02 
8. TAQ-R-P - - - - - - - - 0.09 -0.02 0.08 0.06 0.08 -0.23* 0.02 0.01 -0.15 0.03 0.07 
9. BMQ (M1) - - - - - - - - - 0.55** 0.24 0.30 0.11 -0.14 -0.20 -0.06 0.04 -0.17 -0.04 
10. BMQ (M3) - - - - - - - - - - 0.09 0.05 0.10 0.04 -0.01 -0.04 -0.06 -0.12 -0.03 
11. FIBSER-1 - - - - - - - - - - - 0.79** 0.53** -0.09 -0.02 0.01 0.13 -0.21** 0.22* 
12. FIBSER-2 - - - - - - - - - - - - 0.80** -0.05 0.08 -0.03 0.19 -0.07 0.27* 
13. FIBSER-3 - - - - - - - - - - - - - 0.23* 0.12 0.16 0.43** 0.10 0.41** 
14. BPM-P Ext (B) - - - - - - - - - - - - - - -0.07 0.48** 0.70** 0.02 0.32** 
15. BPM-P Int (B) - - - - - - - - - - - - - - - -0.22* -0.05 0.60** -0.05 
16. BPM-P Att (B) - - - - - - - - - - - - - - - - 0.50** -0.06 0.72** 
17. BPM-P Ext (M3) - - - - - - - - - - - - - - - - - 0.17 0.62** 
18. BPM-P Int (M3) - - - - - - - - - - - - - - - - - - 0.13 
19. BPM-P Att (M3) - - - - - - - - - - - - - - - - - - - 
Note.* p<.05, ** p<.01 
 
Note. B=Baseline; M1=1-month follow-up; M3=3-month follow-up; CEQ-C=Credibility/Expectancy Questionnaire-Child Version; 
CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; URICA-C= University of Rhode Island Change Assessment-Child 
Version; URICA-P= University of Rhode Island Change Assessment-Parent Version; TASC-R=Therapeutic Alliance Scale for 
Children-Revised; WAI-SF=Working Alliance Inventory-Short Form; TAQ-R-C=Therapeutic Alliance Quality Rating-Child Version; 
TAQ-R-P=Therapeutic Alliance Quality Rating-Parent Version; BMQ=Brief Medication Questionnaire; FIBSER-1=Frequency, 
Intensity, and Burden of Side Effects Rating-Item 1 (Frequency); FIBSER-2=Frequency, Intensity, and Burden of Side Effects Rating-
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Item 2 (Intensity); FIBSER-3=Frequency, Intensity, and Burden of Side Effects Rating-Item 3 (Interference); BPM-P Ext=Brief 
Progress Monitor-Parent Version (Externalizing); BPM-P Int=Brief Progress Monitor-Parent Version (Internalizing); BPM-P 
Att=Brief Progress Monitor-Parent Version (Attention Problems) 
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Table 4. Residualized regression relationships for all main effects and significant moderators of main effects 
DV Predictor Moderator
a 
Moderator 
Levelb b (Slope)
c R2d 
TASC-R CEQ-C   0.28** 0.08 
   TASC-R    CEQ-C Alpha-2 Low 0.31** 0.16 
   TASC-R    CEQ-C Alpha-2 High -0.02** 0.16 
   TASC-R    CEQ-C ADHD Low 0.62** 0.15 
   TASC-R    CEQ-C ADHD High 0.18 0.15 
   TASC-R    CEQ-C FIBSER-2 Low  1.03** 0.26 
   TASC-R    CEQ-C FIBSER-2 Med 0.36** 0.26 
   TASC-R    CEQ-C FIBSER-2 High -0.32 0.26 
      
TASC-R CEQ-P   0.18 0.03 
      
TASC-R URICA-C   0.52** 0.24 
      
TASC-R URICA-P   0.07 0.01 
   TASC-R    URICA-P CTM3 Low -0.26* 0.12 
   TASC-R    URICA-P CTM3 High 0.18* 0.12 
   TASC-R    URICA-P Stimulant Low 0.16 0.04 
   TASC-R    URICA-P Stimulant High -0.01* 0.04 
      
WAI-SF CEQ-C   0.11 0.01 
      
WAI-SF CEQ-P   0.22* 0.05 
      
WAI-SF URICA-C   -0.05 0.00 
   WAI-SF    URICA-C Atypical Low -0.01 0.05 
   WAI-SF    URICA-C Atypical High -0.21** 0.05 
      
WAI-SF URICA-P   0.30** 0.09 
      
TAQ-R-C CEQ-C   0.08 0.01 
      
TAQ-R-C CEQ-P   0.13 0.02 
      
TAQ-R-C URICA-C   0.21* 0.04 
      
TAQ-R-C URICA-P   -0.06 0.00 
      
TAQ-R-P CEQ-C   0.11 0.01 
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Table 4. (continued) 
DV Predictor Moderator
a 
Moderator 
Levelb b (Slope)
c R2d 
TAQ-R-P CEQ-P   0.04 0.00 
      
TAQ-R-P URICA-C   0.20** 0.04 
   TAQ-R-P    URICA-C Atypical Low 0.27** 0.09 
   TAQ-R-P    URICA-C Atypical High 0.03** 0.09 
      
TAQ-R-P URICA-P   0.14* 0.02 
  TAQ-R-P   URICA-P Ext Dx Low -0.22* 0.10 
  TAQ-R-P   URICA-P Ext Dx High 0.22** 0.10 
      
BMQ (M1) CEQ-C   -0.15 0.03 
      
BMQ (M1) CEQ-P   -0.34** 0.11 
      
BMQ (M1) URICA-C   -0.28* 0.07 
      
BMQ (M1) URICA-P   0.26 0.07 
      
BMQ (M1) TASC-R   -0.02 0.00 
      
BMQ (M1) WAI-SF   0.00 0.00 
      
BMQ (M1) TAQ-R-C   -0.03 0.00 
   BMQ (M1)   TAQ-R-C Atypical Low -0.07 0.05 
   BMQ (M1)   TAQ-R-C Atypical High 0.14** 0.05 
      
BMQ (M1) TAQ-R-P   0.12 0.02 
      
BMQ (M3) CEQ-C   -0.11 0.03 
      
BMQ (M3) CEQ-P   -0.19* 0.05 
      
BMQ (M3) URICA-C   -0.03 0.02 
      
BMQ (M3) URICA-P   -0.05 0.02 
      
BMQ (M3) TASC-R   0.06 0.02 
      
BMQ (M3) WAI-SF   -0.15 0.04 
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Table 4. (continued) 
DV Predictor Moderator
a 
Moderator 
Levelb b (Slope)c R2d 
BMQ (M3) TAQ-R-C   0.04 0.02 
      
BMQ (M3) TAQ-R-P   0.00 0.02 
      
BPM-P Ext CEQ-C   -0.10 0.01 
   BPM-P Ext    CEQ-C Tic Dx Low -0.18 0.06 
   BPM-P Ext    CEQ-C Tic Dx High 0.04* 0.06 
      
BPM-P Ext CEQ-P   -0.14 0.02 
      
BPM-P Ext URICA-C   -0.05 0.00 
   BPM-P Ext    URICA-C Tic Dx Low -0.16 0.09 
   BPM-P Ext    URICA-C Tic Dx High 0.14** 0.09 
      
BPM-P Ext URICA-P   0.03 0.00 
      
BPM-P Ext TASC-R   -0.07 0.01 
      
BPM-P Ext WAI-SF   0.08 0.01 
   BPM-P Ext    WAI-SF Ext Dx Low 0.40** 0.03 
   BPM-P Ext    WAI-SF Ext Dx High -0.02 0.03 
      
BPM-P Ext TAQ-R-C   0.15 0.02 
      
BPM-P Ext TAQ-R-P   0.01 0.00 
      
BPM-P Ext BMQ (M1)   0.05 0.01 
      
BPM-P Ext BMQ (M3)   -0.06 0.01 
      
BPM-P Int CEQ-C   0.00 0.00 
   BPM-P Int    CEQ-C Atypical Low -0.04 0.04 
   BPM-P Int    CEQ-C Atypical High 0.13** 0.04 
      
BPM-P Int CEQ-P   -0.14 0.02 
      
BPM-P Int URICA-C   0.27** 0.06 
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Table 4. (continued) 
DV Predictor Moderator
a 
Moderator 
Levelb b (Slope)c R2d 
BPM-P Int URICA-P   0.01 0.00 
   BPM-P Int    URICA-P No Prescription Low -0.18* 0.04 
   BPM-P Int    URICA-P No Prescription High 0.08** 0.04 
      
BPM-P Int TASC-R   -0.13 0.02 
   BPM-P Int    TASC-R Atypical Low -0.22* 0.09 
   BPM-P Int    TASC-R Atypical High 0.03** 0.09 
      
BPM-P Int WAI-SF   0.05 0.00 
      
BPM-P Int TAQ-R-C   -0.03 0.00 
      
BPM-P Int TAQ-R-P   0.01 0.00 
   BPM-P Int    TAQ-R-P Atypical Low 0.05 0.06 
   BPM-P Int    TAQ-R-P Atypical High -0.20** 0.06 
      
BPM-P Int BMQ (M1)   -0.18 0.03 
   BPM-P Int    BMQ (M1) Alpha-2 Low -0.18 0.07 
   BPM-P Int    BMQ (M1) Alpha-2 High 0.83** 0.07 
      
BPM-P Int BMQ (M3)   -0.11 0.01 
      
BPM-P Att CEQ-C   -0.03 0.00 
      
BPM-P Att CEQ-P   -0.27* 0.07 
   BPM-P Att    CEQ-P FIBSER-2 Low  0.29 0.18 
   BPM-P Att    CEQ-P FIBSER-2 Med -0.24** 0.18 
   BPM-P Att    CEQ-P FIBSER-2 High -0.77** 0.18 
      
BPM-P Att URICA-C   -0.16 0.02 
      
BPM-P Att URICA-P   0.05 0.00 
      
BPM-P Att TASC-R   -0.15* 0.02 
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Table 4. (continued) 
DV Predictor Moderator
a 
Moderator 
Levelb b (Slope)c R2d 
BPM-P Att WAI-SF   0.14 0.02 
   BPM-P Att    WAI-SF FIBSER-3 Low  -0.54** 0.20 
   BPM-P Att    WAI-SF FIBSER-3 Med 0.11 0.20 
   BPM-P Att    WAI-SF FIBSER-3 High 0.75** 0.20 
   BPM-P Att    WAI-SF CTM1 Low -0.10 0.16 
   BPM-P Att    WAI-SF CTM1 High 0.35** 0.16 
      
BPM-P Att TAQ-R-C   0.07 0.01 
      
BPM-P Att TAQ-R-P   0.06 0.00 
   BPM-P Att    TAQ-R-P CTM3 Low 0.42** 0.04 
   BPM-P Att    TAQ-R-P CTM3 High 0.02 0.04 
      
BPM-P Att BMQ (M1)   0.08 0.01 
   BPM-P Att    BMQ (M1) FIBSER-2 Low  -0.49* 0.17 
   BPM-P Att    BMQ (M1) FIBSER-2 Med 0.06 0.17 
   BPM-P Att    BMQ (M1) FIBSER-2 High 0.61** 0.17 
      
BPM-P Att BMQ (M3)   -0.09 0.01 
Note.* p<.05, ** p<.01 
 
Note. M1=1-month follow-up; M3=3-month follow-up; TASC-R=Therapeutic Alliance Scale for 
Children-Revised; WAI-SF=Working Alliance Inventory-Short Form; TAQ-R-C=Therapeutic 
Alliance Quality Rating-Child Version; TAQ-R-P=Therapeutic Alliance Quality Rating-Parent 
Version; BMQ=Brief Medication Questionnaire; BPM-P Ext=Brief Progress Monitor-Parent 
Version (Externalizing); BPM-P Int=Brief Progress Monitor-Parent Version (Internalizing); 
BPM-P Att=Brief Progress Monitor-Parent Version (Attention Problems); CEQ-
C=Credibility/Expectancy Questionnaire-Child Version; CEQ-P=Credibility/Expectancy 
Questionnaire-Parent Version; URICA-C= University of Rhode Island Change Assessment-
Child Version; URICA-P= University of Rhode Island Change Assessment-Parent Version; 
TASC-R=Therapeutic Alliance Scale for Children-Revised; WAI-SF=Working Alliance 
Inventory-Short Form; TAQ-R-C=Therapeutic Alliance Quality Rating-Child Version; TAQ-R-
P=Therapeutic Alliance Quality Rating-Parent Version; BMQ=Brief Medication 
Questionnaire;Alpha-2=Alpha-2 agonists; FIBSER-2=Frequency, Intensity, and Burden of Side 
Effects Rating-Item 2 (Intensity); CTM1=Concurrent treatment received by 1-month follow-up; 
CTM3=Concurrent treatment received by 3-month follow-up; Atypical=Atypical antipsychotic; 
Ext Dx=Externalizing Diagnosis; Tic Dx=Tic Disorder Diagnosis; FIBSER-3=Frequency, 
Intensity, and Burden of Side Effects Rating-Item 3 (Interference) 
 
aModerators were included in table if they were significant after Holm-Bonferroni correction 
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Table 4. (continued) 
 
bFor continuous moderators, low, medium, high values reflect -1 SD, the mean, and +1 SD 
respectively for the corresponding measure. For dichotomous moderators, low values reflect the 
absence of the moderator (i.e., 0 in dummy-coding), and high values reflect presence of the 
moderator (i.e., 1 in dummy-coding). 
 
cSlopes reflect standardized beta weights for main effects and standardized simple slopes for 
moderators evaluated at the respective moderator level. Significance was evaluated based on 
unstandardized analyses as recommended by Fairchild and McQuillin (2010), and standardized 
results are presented to facilitate comparison across models. 
 
dR2 values reflect amount of variance attributable specifically to the predictor in main effect 
models, and reflect the amount of additional variance attributable to adding the moderator and its 
interaction term in moderation models
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Table 5. Numerical results for indirect effect models tested 
X M Y W
a Va Ua Moderator Levelb 
Std. 
Indirect 
Effectc 
Std. 
Direct 
Effectc 
Std. 
Total 
Effectc 
Expectancies/Motivation Through Alliance to Outcome 
     
CEQ-C TASC-R BPM-P Att ADHD 
  
Low W -0.13 0.00 -0.13 
   
   
High W -0.01 0.00 -0.01 
          
CEQ-C TASC-R BPM-P Att Alpha-2 
  
Low W -0.06 0.01 -0.05 
   
   
High W 0.21* 0.01 0.22 
          
CEQ-C TASC-R BPM-P Att FIBSER-2 
  
Low W -0.17 0.03 -0.14 
    
  
Med W -0.08 0.03 -0.05 
    
  
High W 0.01 0.03 0.04 
          
URICA-C TASC-R BPM-P Att 
    
-0.07 -0.18 -0.24 
          
URICA-P TASC-R BPM-P Att CTM3 
  
Low W 0.05 0.09 0.14 
   
   
High W -0.07 0.09 0.02 
          
URICA-P TASC-R BPM-P Att Stimulant 
  
Low W -0.04 0.08 0.04 
    
  
High W 0.05* 0.08 0.14 
          
CEQ-P WAI-SF BPM-P Att 
 
CTM1 FIBSER-2 Low V, Low U 0.01 -0.01 0.00 
   
 
  High V, Low U 0.25* -0.01 0.25 
   
 
  Low V, Med U 0.01 -0.53** -0.52** 
   
 
  High V, Med U 0.25* -0.53** -0.27 
      Low V, High U 0.01 -1.05** -1.04** 
      High V, High U 0.25* -1.05** -0.79* 
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Table 5. (continued) 
X M Y W
a Va Ua Moderator Levelb 
Std. 
Indirect 
Effectc 
Std. 
Direct 
Effectc 
Std. 
Total 
Effectc 
URICA-P WAI-SF BPM-P Att 
 
CTM1 
 
Low W -0.04 0.07 0.03 
     
 
High W 0.39** 0.07 0.46** 
          
URICA-C WAI-SF BPM-P Att Atypical CTM1 
 
Low W, Low V 0.00 -0.19 -0.19 
     
 
High W, Low V 0.06 -0.19 -0.13 
     
 
Low W, High V -0.04 -0.19 -0.23 
     
 
High W, High V -0.93** -0.19 -1.13** 
          
URICA-P WAI-SF BPM-P Att 
 
FIBSER-3 
 
Low V -0.16 0.01 -0.15 
     
 
Med V 0.07 0.01 0.08 
     
 
High V 0.30** 0.01 0.31 
          
URICA-C WAI-SF BPM-P Att Atypical FIBSER-3 
 
Low W, Low V 0.01 -0.21 -0.20 
     
 
High W, Low V 0.35* -0.21 0.14 
     
 
Low W, Med V 0.00 -0.21 -0.21 
     
 
High W, Med V -0.16 -0.21 -0.37 
     
 
Low W, High V -0.02 -0.21 -0.23 
     
 
High W, High V -0.66** -0.21 -0.87** 
          
URICA-C TAQ-R-P BPM-P Att Atypical CTM3 
 
Low W, Low V 0.27* -0.39* -0.13 
     
 
High W, Low V -0.49** -0.39* -0.88** 
     
 
Low W, High V 0.00 -0.39* -0.39* 
     
 
High W, High V -0.01 -0.39* -0.40 
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Table 5. (continued) 
X M Y W
a Va Ua Moderator Levelb 
Std. 
Indirect 
Effectc 
Std. 
Direct 
Effectc 
Std. 
Total 
Effectc 
URICA-P TAQ-R-P BPM-P Att Ext Dx CTM3 
 
Low W, Low V -0.18 0.23 0.05 
     
 
High W, Low V 0.32** 0.23 0.54** 
     
 
Low W, High V 0.04 0.23 0.27 
     
 
High W, High V -0.07 0.23 0.15 
          
CEQ-P WAI-SF BPM-P Ext 
 
Ext Dx 
 
Low V 0.18 -0.51** -0.32 
     
 
High V -0.04 -0.51** -0.54** 
          
URICA-P WAI-SF BPM-P Ext 
 
Ext Dx 
 
Low V 0.18* -0.09 0.09 
     
 
High V -0.05 -0.09 -0.14 
          
URICA-C WAI-SF BPM-P Ext Atypical Ext Dx Tic Dx Low W, Low V, Low U -0.01 -0.39* -0.39 
      Low W, Low V, High U -0.01 1.11** 1.11** 
      Low W, High V, Low U 0.00 -0.39* -0.38 
      Low W, High V, High U 0.00 1.11** 1.12** 
      High W, Low V, Low U -0.48* -0.39* -0.86** 
      High W, Low V, High U -0.48* 1.11** 0.64 
      High W, High V, Low U 0.21 -0.39* -0.18 
      High W, High V, High U 0.21 1.11** 1.32** 
          
CEQ-C TASC-R BPM-P Int ADHD Atypical Atypical Low W, Low V and U -0.19 0.06 -0.13 
      High W, Low V and U -0.02 0.06 0.04 
      Low W, High V and U 0.59** 0.46** 1.05** 
      High W, High V and U 0.05 0.46** 0.51* 
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Table 5. (continued) 
X M Y W
a Va Ua Moderator Levelb 
Std. 
Indirect 
Effectc 
Std. 
Direct 
Effectc 
Std. 
Total 
Effectc 
CEQ-C TASC-R BPM-P Int Alpha-2 Atypical Atypical Low W, Low V and U -0.07 -0.02 -0.09 
      High W, Low V and U 0.26* -0.02 0.24 
      Low W, High V and U 0.28* 0.56** 0.83** 
      High W, High V and U -0.96 0.56** -0.40 
          
CEQ-C TASC-R BPM-P Int FIBSER-2 Atypical Atypical Low W, Low V and U -0.24* -0.03 -0.27** 
      Med W, Low V and U -0.11* -0.03 -0.14* 
      High W, Low V and U 0.03 -0.03 0.00 
      Low W, High V and U 0.80* 0.53** 1.34** 
      Med W, High V and U 0.36* 0.53** 0.89** 
      High W, High V and U -0.09 0.53** 0.45* 
          
URICA-C TASC-R BPM-P Int 
 
Atypical 
 
Low V -0.31** 0.57** 0.26* 
     
 
High V 0.30 0.57** 0.87** 
          
URICA-P TASC-R BPM-P Int CTM3 Atypical 
 
Low W, Low V 0.05 0.05 0.10 
     
 
High W, Low V -0.05 0.05 -0.01 
     
 
Low W, High V -0.22 0.05 -0.17 
     
 
High W, High V 0.23 0.05 0.28 
          
URICA-P TASC-R BPM-P Int Stimulant Atypical 
 
Low W, Low V -0.05 0.05 -0.01 
     
 
High W, Low V 0.07 0.05 0.10 
     
 
Low W, High V 0.15 0.05 0.19 
     
 
High W, High V -0.24 0.05 -0.21 
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Table 5. (continued) 
X M Y W
a Va Ua Moderator Levelb 
Std. 
Indirect 
Effectc 
Std. 
Direct 
Effectc 
Std. 
Total 
Effectc 
URICA-C TAQ-R-P BPM-P Int Atypical Atypical 
 
Low V 0.00 0.29** 0.29** 
     
 
High V 0.73** 0.29** 1.02** 
          
URICA-P TAQ-R-P BPM-P Int Ext Dx Atypical 
 
Low W, Low V -0.02 0.05 0.03 
     
 
High W, Low V 0.03 0.05 0.08 
     
 
Low W, High V 0.29** 0.05 0.34** 
     
 
High W, High V -0.50** 0.05 -0.45** 
       
       
Expectancies/Motivation Through Adherence to Outcome 
     
CEQ-P BMQ (M1) BPM-P Att 
 
FIBSER-2 FIBSER-2 Low V and U 0.15 0.11 0.27 
      Med V and U 0.02 -0.47** -0.45** 
      High V and U -0.12 -1.05** -1.17** 
          
URICA-C BMQ (M1) BPM-P Att 
 
FIBSER-2 
 
Low V 0.17 -0.44* -0.27 
     
 
Med V -0.01 -0.44* -0.45 
     
 
High V -0.19 -0.44* -0.63* 
          
CEQ-P BMQ (M1) BPM-P Int 
 
Alpha-2 
 
Low V 0.14 -0.31 -0.18 
     
 
High V -2.55** -0.31 -2.86** 
          
URICA-C BMQ (M1) BPM-P Int 
 
Alpha-2 
 
Low V 0.03 0.47** 0.50** 
     
 
High V -2.75* 0.47** -2.28 
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Table 5. (continued) 
X M Y W
a Va Ua Moderator Levelb 
Std. 
Indirect 
Effectc 
Std. 
Direct 
Effectc 
Std. 
Total 
Effectc 
Alliance Through Adherence to Outcome 
      
TAQ-R-C BMQ (M1) BPM-P Att Atypical FIBSER-2 
 
Low W, Low V 0.03 0.14 0.17 
     
 
High W, Low V -0.43 0.14 -0.29 
     
 
Low W, Med V -0.01 0.14 0.13 
     
 
High W, Med V 0.10 0.14 0.24 
     
 
Low W, High V -0.04 0.14 0.10 
     
 
High W, High V 0.63* 0.14 0.77* 
          
TAQ-R-C BMQ (M1) BPM-P Int Atypical Alpha-2 
 
Low W, Low V 0.01 -0.06 -0.05 
     
 
High W, Low V -0.23 -0.06 -0.29 
     
 
Low W, High V -0.30 -0.06 -0.36 
     
 
High W, High V 6.31* -0.06 6.24* 
Note.* p<.05, ** p<.01 
 
Note. M1=1-month follow-up; M3=3-month follow-up; CEQ-C=Credibility/Expectancy Questionnaire-Child Version; URICA-C= 
University of Rhode Island Change Assessment-Child Version; URICA-P= University of Rhode Island Change Assessment-Parent 
Version; CEQ-P=Credibility/Expectancy Questionnaire-Parent Version; TAQ-R-C=Therapeutic Alliance Quality Rating-Child 
Version; TASC-R=Therapeutic Alliance Scale for Children-Revised; WAI-SF=Working Alliance Inventory-Short Form; TAQ-R-
P=Therapeutic Alliance Quality Rating-Parent Version; BMQ=Brief Medication Questionnaire; Y: BPM-P Att=Brief Progress 
Monitor-Parent Version (Attention Problems); BPM-P Ext=Brief Progress Monitor-Parent Version (Externalizing); BPM-P Int=Brief 
Progress Monitor-Parent Version (Internalizing); Alpha-2=Alpha-2 agonists; Atypical=Atypical antipsychotic; FIBSER-2=Frequency, 
Intensity, and Burden of Side Effects Rating-Item 2 (Intensity); FIBSER-3=Frequency, Intensity, and Burden of Side Effects Rating-
Item 3 (Interference); CTM1=Concurrent treatment received by 2-month follow-up; CTM3=Concurrent treatment received by 3-
month follow-up; Ext Dx=Externalizing Diagnosis; Tic Dx=Tic Disorder Diagnosis  
 
aW reflects moderator of X-M relationship, V reflects moderator of M-Y relationship, and U reflects moderator of c’ 
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Table 5 (continued.) 
 
bFor continuous moderators, low, medium, high values reflect -1 SD, the mean, and +1 SD respectively for the corresponding 
measure. For dichotomous moderators, low values reflect the absence of the moderator (i.e., 0 in dummy-coding), and high values 
reflect presence of the moderator (i.e., 1 in dummy-coding). 
 
cSlopes reflect standardized effects. Significance was evaluated based on unstandardized analyses as recommended by Fairchild and 
McQuillin (2010), and standardized results are presented to facilitate interpretation as recommended by Wen and Fan (2015). 
 
 75 
75 
 
 
 
 
 
 
 
 
 
Figure 1. Hypothesized model of psychosocial variables and treatment outcome in pediatric 
psychiatry, reflecting all bivariate relationships tested in the present study.   
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Figure 2. Graphical depiction of moderated mediation models tested, including the overall 
framework (top) and specific 2-mediator model (bottom) 
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APPENDIX A: 
 
URICA-P 
 
The following questions address how you view symptoms of depression and anxiety for your 
child. 
 
 
Item 
 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Undecided 
4 
Agree 
5 
Strongly 
Agree 
1) As far as I'm concerned, my child 
doesn’t have any problems that 
need changing. 
     
2) I think my child might be ready for 
some improvement. 
     
3) I am doing something about the 
problems that had been bothering 
my child. 
     
4) It might be worthwhile to work on 
my child’s problem. 
     
5) My child isn’t the problem one. It 
doesn't make much sense for 
him/her to be here. 
     
6) It worries me that my child might 
slip back on a problem he/she has 
already changed, so I am here to 
seek help for him/her. 
 
 
 
 
 
 
 
 
 
 
7) I am finally doing some work on 
my child’s problem. 
     
8) I've been thinking that I might want 
to change something about my 
child. 
     
9) My child has been successful in 
working on his/her problem but I'm 
not sure I can keep up the help on 
my own. 
 
 
 
 
 
 
 
 
 
 
10) At times my child’s problem is 
difficult, but I'm working to help. 
     
11) Being here is pretty much a waste 
of time because the problem doesn't 
have to do with my child. 
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12) I'm hoping this place will help me 
to better understand my child’s 
problem. 
     
13) I guess my child has faults, but 
there's nothing that he/she really 
needs to change. 
     
14) I am really working hard to help 
my child. 
     
15) My child has a problem and I 
really think I should work to help. 
     
16) I'm not following through with 
helping my child as well as I had 
hoped, and I'm here to prevent a 
relapse of the problem. 
 
 
 
 
 
 
 
 
 
 
17) Even though I'm not always 
successful helping my child, I am 
at least working on his/her 
problem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18) I thought once I had resolved my 
child’s problem I would be free of 
it, but sometimes I still find myself 
struggling to help. 
 
 
 
 
 
 
 
 
 
 
19) I wish I had more ideas on how to 
solve my child’s problem. 
     
20) I have started working on my 
child’s problems but I would like 
help. 
     
21) Maybe this place will be able to 
help my child. 
     
22) I may need a boost right now to 
help me maintain the changes I've 
already made in helping my child. 
 
 
 
 
 
 
 
 
 
 
23) I may be able to deal with my 
child’s problem better, but I don’t 
really think so 
     
24) I hope that someone here will have 
some good advice for my child. 
     
25) Anyone can talk about helping 
their children; I'm actually doing 
something about it. 
     
26) All this talk about psychiatry is 
boring. Why can't people just 
forget about their problems? 
 
 
 
 
 
 
 
 
 
 
27) I'm here to prevent my child from 
having a relapse of his/her 
problem. 
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28) It is frustrating, but I feel my child 
might be having a recurrence of a 
problem I thought had been 
resolved. 
 
 
 
 
 
 
 
 
 
 
29) I have worries about my child’s 
symptoms but so does the next 
person. Why spend time thinking 
about them? 
 
 
 
 
 
 
 
 
 
 
30) I am actively working on my 
child’s problem. 
     
31) I would rather cope with my 
child’s faults than try to change 
them. 
     
32) After all I had done to try to 
change my child’s problem, every 
now and again it comes back to 
haunt me.  
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APPENDIX B: 
 
URICA-C 
 
The following questions address how you view your thoughts and feelings of being down or 
nervous. 
 
Item 1 
Strongly 
Disagree 
2 
Disagree 
3 
Undecided 
4 
Agree 
5  
Strongly 
Agree 
1) As far as I'm concerned, I 
don't have any problems that 
need changing. 
     
2) I think I might be ready for 
some self-improvement. 
     
3) I am doing something about 
the problems that had been 
bothering me. 
     
4) It might be worthwhile to 
work on my problem. 
     
5) I'm not the problem one. It 
doesn't make much sense for 
me to be here. 
     
6) It worries me that I might slip 
back on a problem I have 
already changed, so I am here 
to seek help. 
 
 
 
 
 
 
 
 
 
 
7) I am finally doing some work 
on my problem. 
     
8) I've been thinking that I might 
want to change something 
about myself. 
     
9) I have been successful in 
working on my problem but 
I'm not sure I can keep up the 
effort on my own. 
 
 
 
 
 
 
 
 
 
 
10) At times my problem is 
difficult, but I'm working 
on it. 
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11) Being here is pretty much a 
waste of time for me because 
the problem doesn't have to do 
with me. 
 
 
 
 
 
 
 
 
 
 
12) I'm hoping this place will help 
me to better understand 
myself. 
     
13) I guess I have faults, but 
there's nothing that I really 
need to change. 
     
14) I am really working hard to 
change. 
     
15) I have a problem and I really 
think I should work at it. 
     
16) I'm not following through 
with what I had already 
changed as well as I had 
hoped, and I'm here to prevent 
a relapse of the problem. 
 
 
 
 
 
 
 
 
 
 
17) Even though I'm not always 
successful in changing, I am 
at least working on my 
problem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18) I thought once I had resolved 
my problem I would be free of 
it, but sometimes I still find 
myself struggling with it. 
 
 
 
 
 
 
 
 
 
 
19) I wish I had more ideas on 
how to solve the problem. 
     
20) I have started working on my 
problems but I would like 
help. 
     
21) Maybe this place will be able 
to help me. 
     
22) I may need a boost right now 
to help me maintain the 
changes I've already made. 
 
 
 
 
 
 
 
 
 
 
23) I may be able to deal with my 
problem better, but I don’t 
really think so. 
     
24) I hope that someone here will 
have some good advice for 
me. 
     
 103 
 
25) Anyone can talk about 
changing; I'm actually doing 
something about it. 
     
26) All this talk about psychiatry 
is boring. Why can't people 
just forget about their 
problems? 
 
 
 
 
 
 
 
 
 
 
27) I'm here to prevent myself 
from having a relapse of my 
problem. 
     
28) It is frustrating, but I feel I 
might be having a recurrence 
of a problem I thought I had 
resolved. 
 
 
 
 
 
 
 
 
 
 
29) I have worries but so does the 
next person. Why spend time 
thinking about them? 
 
 
 
 
 
 
 
 
 
 
30) I am actively working on my 
problem. 
     
31) I would rather cope with my 
faults than try to change them. 
     
32) After all I had done to try to 
change my problem, every 
now and again it comes back 
to haunt me.  
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APPENDIX C: 
TAQ-R 
All questions below refer to the session that you just completed with this family. Please select 
one answer for each question. 
Did the youth participate in the session that you just had for him or her? 
 
      
   Yes  No 
 
Did the youth’s caregiver participate in the session that you just had for this youth? 
 
      
   Yes  No 
 
 
  Very Poor Poor Satisfactory Good Excellent 
1. In this session, how would you 
describe your relationship with 
this YOUTH? 
 
     
2. In this session, how would you 
describe your relationship with 
this CAREGIVER? 
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APPENDIX D: 
 
  WAI-SF 
 
Following are sentences that describe some of the different ways a person might think or feel about his or her family’s counselor. Using the 
following 7-point scale, please respond to every item with your first impressions of your counselor: 
 
 
 
 
 
 
Never 
 
 
 
 
Rarely 
 
 
 
 
Occasionally 
 
 
 
 
Sometimes 
 
 
 
 
Often 
 
 
 
 
Very Often 
 
 
 
 
Always 
1.  The counselor and I agree about the things that 
my family needs to do in therapy to help 
improve our situation. 
1 2 3 4 5 6 7 
2.  What we are doing in counseling gives me new 
ways of looking at my family’s problems. 
1 2 3 4 5 6 7 
3.  I believe the counselor likes my family.  1 2 3 4 5 6 7 
4.  The counselor does not understand what my 
family is trying to accomplish in counseling.  
1 2 3 4 5 6 7 
5.  I am confident in the counselor’s ALLIANCE 
AND MEDICATION ADHERENCE to 
help my family.  
1 2 3 4 5 6 7 
6.  The counselor and my family are working 
towards mutually agreed upon goals.  
1 2 3 4 5 6 7 
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7.  I feel that the counselor appreciates my 
family. 
1 2 3 4 5 6 7 
8. We agree on what is important for my family 
to work on.  
1 2 3 4 5 6 7 
9. My family has built a mutual trust with the 
counselor.  
1 2 3 4 5 6 7 
10. My family and the counselor have different 
ideas on what our real problems are. 
1 2 3 4 5 6 7 
11. We have established a good understanding of 
the kind of changes that would be good for my 
child/family. 
1 2 3 4 5 6 7 
12. I believe the way we are working with my 
family’s problem is correct. 
1 2 3 4 5 6 7 
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APPENDIX E: 
 
CEQ-P 
 
The following questions address how you believe this treatment will affect your child’s 
troublesome symptoms of depression and anxiety. 
 
1. By the end of the therapy period, how much improvement in your child’s problem behavior do 
you really feel will occur? 
 
0%      10%      20%     30%       40%      50%      60%      70%    80%      90%     100% 
 
2. By the end of therapy, how much improvement in your child’s behavior do you think will 
have occurred? 
 
1                  2              3            4                     5                  6             7             8               9 
Not at all                                                    Somewhat                                                Very much 
 
3. At this point, take a minute to think about how much do you really feel that therapy will help 
to reduce your child’s problem behaviors? 
 
0%      10%      20%     30%       40%      50%      60%      70%    80%      90%     100% 
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APPENDIX F: 
         BMQ 
1. Please list below all of the medications your child took in the PAST WEEK. For each 
medication you list, please answer each of the questions in the box below. 
 
If he/she has stopped medication completely for these conditions since he/she first saw the 
psychiatrist, please write “Stopped” after listing the medication and the reason for stoppage (for 
example, side effects). 
 
Medication name 
and strength  
(if stopped, please 
provide the reason) 
How many 
days did 
he/she take it? 
How many times 
per day did 
he/she take it? 
How many 
pills did 
he/she take 
each time? 
How many times 
did he/she miss 
taking a pill? 
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APPENDIX G: 
       SACA 
In the last 3 months, has your child received outpatient or inpatient help from any of the 
following sources? 
 
 
 
 
 
IF YES: 
COL A 
NUMBER OF HOURS 
OR DAYS OF 
SERVICE  
 
 
IF YES: 
CHECK TYPES OF SERVICES 
GIVEN: 
1.  Community mental health center or other 
outpatient mental health clinic 
 
 
 NO YES DK   
 
 
 
__ __ __ hrs. 
 
 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
__case management 
2. Professional like a psychologist, 
psychiatrist, social worker, or family 
counselor not part of a service or clinic 
already mentioned 
 
 
NO YES DK   
 
 
__ __ __hrs. 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
__case management 
3. Partial hospitalization or day treatment 
program 
 
 
 
 NO YES DK   
 
 
 
 
__ __ __ hrs. 
 
 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
4. Drug or alcohol clinic 
 
NO YES DK   
 
 
__ __ __hrs. 
 
 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
5. Therapist or counselor or family 
preservation worker who came to your 
home 
 
 
 NO YES DK   
 
__ __ __ hrs. 
 
 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
__case management 
6. Emergency room for problems with 
behaviors or feelings 
 
 
 NO YES DK 
 
__ __ __hrs. 
__assessment 
__individual treatment/therapy 
__family/parent treatment/ed 
__medication 
7.  Pediatrician or family doctor for 
problems with behaviors or feelings  
 
 
 NO YES DK   
 
__ __ __hrs. 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
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8.   Probation or juvenile corrections officer 
or a court counselor  
 
 
 NO YES DK   
 
__ __ __hrs. 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
9.  Priest, Minister or Rabbi for problems 
with behaviors or feelings  
 
 NO YES DK   
 
__ __ __hrs. 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__education/training 
10.  Acupuncturist/Chiropractor   
 
 NO YES DK   
 
 
__ __ __hrs. 
__assessment 
__individual treatment/therapy 
__group treatment 
__family/parent treatment/ed 
__medication 
__education/training 
11.  Crisis hotline   
 NO YES DK   
__ __ __hrs.  
12.  Any self-help group like Alcoholics 
Anonymous or peer counseling  
 
 NO YES DK   
__ __ __hrs.  
 
13.     Other: describe____________________ 
 
 NO YES DK   
 
____ __ __hrs.. 
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APPENDIX H: 
 
FIBSER 
 
INSTRUCTIONS: Select the best response for the following three questions. 
 
1)  Choose the response that best describes the frequency (how often) of the side effects of 
the medication you have taken within the past week for your depression. Do not rate side 
effects if you believe they are due to treatments that you are taking for medical conditions 
other than depression or anxiety. Rate the frequency of these side effects for the past 
week. 
 
No side 
effects 
Present 
10% of the 
time 
Present 
25% of the 
time 
Present 
50% of the 
time 
Present 
75% of the 
time 
Present 
90% of the 
time 
Present all 
the time 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
2)  Choose the response that best describes the intensity (how severe) of the side effects that 
you believe are due to the medication you have taken within the last week for your 
depression or anxiety. Rate the intensity of the side effect(s), when they occurred, over 
the last week. 
 
No side 
effects 
Trivial Mild Moderate Marked Severe Intolerable 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
3) Choose the response that best describes the degree to which antidepressant medication 
side effects that you have had over the last week have interfered with your day to day 
functions. 
 
No 
impairment 
Minimal 
impairment 
Mild 
impairment  
Moderate 
impairment 
Marked 
impairment 
Severe 
impairment 
Unable to 
function 
due to 
impairment 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
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APPENDIX I: 
PRISE 
 
Please indicate all symptoms you have experienced in the past week. These symptoms may or 
may not have been caused by your treatment. 
 
1. GASTROINTESTINAL 4. NERVOUS SYSTEM 
1.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause:  
 Diarrhea 
 Constipation 
 Dry Mouth 
 Nausea/vomiting 
 No symptoms in this category 
1.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
4.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Headache 
 Tremors 
 Poor coordination 
 Dizziness 
 No symptoms in this category 
4.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
2. HEART 5. EYES/EARS 
2.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Palpitation (skipping a beat) 
 Dizziness on standing 
 Chest pain 
 No symptoms in this category 
2.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
5.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Blurred Vision 
 Ringing in ears 
No symptoms in this category 
5.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
3. SKIN  6. GENITAL/URINARY 
3.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Rash 
 Increased perspiration 
 Itching  
 Dry skin 
 No symptoms in this category 
6.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Difficulty urinating 
 Painful Urination 
 Frequent urination 
 Menstrual irregularity 
 No symptoms in this category 
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3.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
6.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
 
7. SLEEP 
 
8. OTHER 
7.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Difficulty sleeping 
 Sleeping too much 
 No symptoms in this category 
7.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
8.1 Check ALL symptoms that you have 
experienced during the past week regardless 
of cause: 
 Anxiety                                     
 Poor concentration                   
 General malaise                          
 Restlessness                                
 Fatigue 
 Decreased energy 
 Other ___________________________ 
 No symptoms in this category 
8.2 If you had any symptoms over the last 
week, how bad was your WORST symptom? 
 Tolerable 
 Distressing 
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APPENDIX J: 
 
TASC-R 
 
Please read the sentences below about this meeting you just had with your therapist. After 
reading each sentence, decide how much the sentence is like you. There are no right or wrong 
answers for this questionnaire, just how you feel. 
 
1. I liked spending time with my therapist. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
2. I found it hard to work with my therapist on solving problems in my life. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
3. I felt like my therapist was on my side and tried to help me. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
4. I worked with my therapist on solving my problems. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
5. When I was with my therapist, I wanted the session to end quickly. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
6. I look forward to meeting with my therapist again. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
7. I felt like my therapist spent too much time working on my problems. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
8. I’d rather have done something other than meet with my therapist. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
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9. I used my time with my therapist to make changes in my life. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
10. I like my therapist. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
11. I would rather have not worked on my problems with my therapist. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
 
12. I think my therapist and I worked well together on dealing with my problems. 
          1                          2                                    3                                    4 
Not Like Me     A Little Like Me          Mostly Like Me          Very Much Like Me 
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APPENDIX K: 
 
CEQ-C 
 
These questions address how you believe this treatment will affect your troublesome thoughts 
and feelings of being sad, down, or nervous. 
 
 
1. By the end of the therapy period, how much improvement in your symptoms do you think will 
occur?  
 
0%      10%      20%     30%       40%      50%      60%      70%    80%      90%     100% 
 
 
2. At this point, how much do you really feel that therapy will help to reduce your symptoms? 
 
1                 2              3            4                     5                  6             7             8               9 
Not at all                                                    Somewhat                                                Very much 
 
3. By the end of the treatment period, how much improvement do you really feel will occur? 
 
0%      10%      20%     30%       40%      50%      60%      70%    80%      90%     100% 
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APPENDIX L:  
 
Documentation of Institutional Review Board Approval 
 
 
